FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Francis Giles

Research Profile

Chemicals & Drugs

Disorders

Concepts & Ideas

Procedures

Physiology

Drug Resistance, Neoplasm

Co-author Network

Publications

TOP 3
Elias Jabbour; M Baccarani; Kapil N Bhalla; Jorge Cortes; N Gattermann; Francis Giles; A Hochhaus; T P Hughes; D-W Kim; R A Larson; P D le Coutre; giovanni martinelli; O G Ottmann; Javier Pinilla-Ibarz; J P Radich; John Reynolds; G Saglio; R C Woodman; Hagop M Kantarjian
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Francis Giles; Bjorn Gjertsen; Boris Labar; François-Xavier Mahon; Ronan T Swords; Anna Turkina; Gianantonio Rosti
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
Kevin Robert Kelly; Deva Mahalingam; Babatunde Oyajobi; Jennifer Carew; M Coffey; C M Espitia; Francis Giles; Steffan Nawrocki
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Francis Giles (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Elias Jabbour; M Baccarani; Kapil N Bhalla; Jorge Cortes; N Gattermann; Francis Giles; A Hochhaus; T P Hughes; D-W Kim; R A Larson; P D le Coutre; giovanni martinelli; O G Ottmann; Javier Pinilla-Ibarz; J P Radich; John Reynolds; G Saglio; R C Woodman; Hagop M Kantarjian
Prediction of outcomes in patients with Ph+ chronic myeloid leukemia in chronic phase treated with nilotinib after imatinib resistance/intolerance.
Leukemia 2013;27(4):907-13.
2012: Francis Giles; Bjorn Gjertsen; Boris Labar; François-Xavier Mahon; Ronan T Swords; Anna Turkina; Gianantonio Rosti
Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
European journal of clinical investigation 2012;42(9):1016-26.
2012: Kevin Robert Kelly; Deva Mahalingam; Babatunde Oyajobi; Jennifer Carew; M Coffey; C M Espitia; Francis Giles; Steffan Nawrocki
Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma.
Oncogene 2012;31(25):3023-38.
2011: Ronan T Swords; David J Bearss; Jennifer Carew; Kevin Robert Kelly; Deva Mahalingam; Steffan Nawrocki; John Sarantopoulos; Francis Giles
The Pim kinases: new targets for drug development.
Current drug targets 2011;12(14):2059-66.
2011: Deva Mahalingam; E C Medina; P Taverna; David J Bearss; Jennifer Carew; G Choy; C M Espitia; J A Esquivel; Francis Giles; Kevin Robert Kelly; Steffan Nawrocki
Targeting PIM kinase enhances the activity of sunitinib in renal cell carcinoma.
British journal of cancer 2011;105(10):1563-73.
2011: W Ma; Francis Giles; X Zhang; X Wang; Z Zhang; T-S Lee; C-H Yeh; Maher Albitar
Three novel alternative splicing mutations in BCR-ABL1 detected in CML patients with resistance to kinase inhibitors.
International journal of laboratory hematology 2011;33(3):326-31.
2011: Kevin Z Qu; Ke Zhang; Wanlong Ma; Hairong Li; Xiuqiang Wang; Xi Zhang; Francis Giles; Michelle Lai; Nezam H Afdhal; Maher Albitar
Ubiquitin-proteasome profiling for enhanced detection of hepatocellular carcinoma in patients with chronic liver disease.
Journal of gastroenterology and hepatology 2011;26(4):751-8.
2010: Ronan T Swords; Kevin Robert Kelly; Stephen C Cohen; Larry J Miller; Thomas E Philbeck; Sander O Hacker; Cathy J Spadaccini; Francis Giles; Andrew Brenner
Rotary powered device for bone marrow aspiration and biopsy yields excellent specimens quickly and efficiently.
Journal of clinical pathology 2010;63(6):562-5.
2010: Adam Abdool; Chen-Hsiung Yeh; Andrew Lamb; Susan O'Brien; JeanMarie Bruey; Francis Giles; Maher Albitar
Circulating CD33 and its clinical value in acute leukemia.
Experimental hematology 2010;38(6):462-71.
2010: Ronan T Swords; Kevin Robert Kelly; Peter G Smith; James J Garnsey; Deva Mahalingam; Ernest Medina; Kelli Oberheu; Swaminathan Padmanabhan; Michael O'Dwyer; Steffan Nawrocki; Francis Giles; Jennifer Carew
Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia.
Blood 2010;115(18):3796-800.
2010: Gary J Schiller; Susan M O'Brien; Arnaud Pigneux; Daniel J DeAngelo; Norbert Vey; Jonathan Kell; Scott Solomon; Robert K Stuart; Verena Karsten; Ann L Cahill; Maher X Albitar; Francis Giles
Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(5):815-21.
2010: C Tanaka; O Q P Yin; V Sethuraman; T Smith; X Wang; K Grouss; H Kantarjian; Francis Giles; O G Ottmann; L Galitz; H Schran
Clinical pharmacokinetics of the BCR-ABL tyrosine kinase inhibitor nilotinib.
Clinical pharmacology and therapeutics 2010;87(2):197-203.
2010: W Ma; H Kantarjian; X Zhang; C-H Yeh; Z J Zhang; S Verstovsek; S O'Brien; Francis Giles; M Albitar
Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology.
International journal of laboratory hematology 2010;32(1 Pt 2):95-102.
2010: Carmel G Cronin; Ronan Swords; Mylene T Truong; Chitra Viswanathan; Eric M Rohren; Francis Giles; Michael O'Dwyer; John F Bruzzi
Clinical utility of PET/CT in lymphoma.
AJR. American journal of roentgenology 2010;194(1):W91-W103.
2010: Deva Mahalingam; Ernest C Medina; Juan A Esquivel; Claudia M Espitia; Sabrina Smith; Kelli Oberheu; Ronan Swords; Kevin Robert Kelly; Monica Mita; Catalin Mita; Jennifer Carew; Francis Giles; Steffan Nawrocki
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(1):141-53.
2010: Ronan Swords; Deva Mahalingam; Michael O'Dwyer; Corrado Santocanale; Kevin Robert Kelly; Jennifer Carew; Francis Giles
Cdc7 kinase - a new target for drug development.
European journal of cancer (Oxford, England : 1990) 2010;46(1):33-40.
2009: Franck E Nicolini; Michael J Mauro; Giovanni Martinelli; Dong-Wook Kim; Simona Soverini; Martin C Müller; Andreas Hochhaus; Jorge Cortes; Charles Chuah; Inge H Dufva; Jane F Apperley; Fumiharu Yagasaki; Jay D Pearson; Senaka Peter; Cesar Sanz-Rodriguez; Claude Preudhomme; Francis Giles; John M Goldman; Wei Zhou
Epidemiologic study on survival of chronic myeloid leukemia and Ph(+) acute lymphoblastic leukemia patients with BCR-ABL T315I mutation.
Blood 2009;114(26):5271-8.
2009: Kamalesh K Sankhala; Devesh M Pandya; John Sarantopoulos; Scott A Soefje; Francis Giles; Sant P Chawla
Prevention of chemotherapy induced nausea and vomiting: a focus on aprepitant.
Expert opinion on drug metabolism & toxicology 2009;5(12):1607-14.
2009: Francis Giles; Norbert Vey; Daniel J DeAngelo; Karen Seiter; Wendy Stock; Robert Stuart; Darinka Boskovic; Arnaud Pigneux; Martin S Tallman; Joseph Brandwein; Jonathan Kell; Tadeusz Robak; Peter Staib; Xavier Thomas; Ann Cahill; Maher Albitar; Susan O'Brien
Phase 3 randomized, placebo-controlled, double-blind study of high-dose continuous infusion cytarabine alone or with laromustine (VNP40101M) in patients with acute myeloid leukemia in first relapse.
Blood 2009;114(19):4027-33.
2009: Susannah Cooper; Francis Giles; Michael R Savona
Overcoming resistance in chronic myelogenous leukemia.
Leukemia & lymphoma 2009;50(11):1785-93.
2009: Deva Mahalingam; Catalin Mita; Kamalesh Sankhala; Ronan Swords; Kevin Robert Kelly; Francis Giles; Monica Mita
Targeting sarcomas: novel biological agents and future perspectives.
Current drug targets 2009;10(10):937-49.
2009: Jorge E Cortes; Hagop M Kantarjian; Stuart L Goldberg; Bayard L Powell; Francis Giles; Meir Wetzler; Luke Akard; John M Burke; Robert Kerr; Mansoor Saleh; August Salvado; Karen McDougall; Maher Albitar; Jerald P Radich
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4754-9.
2009: Francis Giles; M O'Dwyer; R Swords
Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia.
Leukemia 2009;23(10):1698-707.
2009: Francis Giles
Laromustine: the return of alkylators to non-myeloablative therapy of AML.
Leukemia research 2009;33(8):1022-3.
2009: Kevin Robert Kelly; Steffan Nawrocki; Catalin Mita; Matthew Coffey; Francis Giles; Monica Mita
Reovirus-based therapy for cancer.
Expert opinion on biological therapy 2009;9(7):817-30.
2009: James W Freeman; Yubao Wang; Francis Giles
Epigenetic modulation and attacking the hedgehog pathway: potentially synergistic therapeutic targets for pancreatic cancer.
Cancer biology & therapy 2009;8(14):1340-2.
2009: Maher Albitar; Steven Potts; Francis Giles; Susan O'Brien; Iman Jilani; Amber C Donahue; Elihu H Estey; Andrew Lamb
Proteomics-based prediction of clinical response in acute myeloid leukemia.
Experimental hematology 2009;37(7):784-90.
2009: Deva Mahalingam; Kevin Robert Kelly; Ronan T Swords; Jennifer Carew; Steffan Nawrocki; Francis Giles
Emerging drugs in the treatment of pancreatic cancer.
Expert opinion on emerging drugs 2009;14(2):311-28.
2009: Wanlong Ma; Andrew Lamb; Benjamin Bekele; Amber C Donahue; Xi Zhang; Zhong J Zhang; Susan O'Brien; Elihu Estey; Zeev Estrov; Jorge Cortes; Michael Keating; Francis Giles; Maher Albitar
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(11):3820-6.
2009: Deva Mahalingam; R Swords; Jennifer Carew; Steffan Nawrocki; Kapil N Bhalla; Francis Giles
Targeting HSP90 for cancer therapy.
British journal of cancer 2009;100(10):1523-9.
2009: April L Risinger; Francis Giles; Susan Mooberry
Microtubule dynamics as a target in oncology.
Cancer treatment reviews 2009;35(3):255-61.
2009: Tai-Sung Lee; Wanlong Ma; Xi Zhang; Francis Giles; Andrew Lamb; Maher Albitar
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations.
Cancer 2009;115(8):1692-700.
2009: Francis Giles
New directions in the treatment of imatinib failure and/or resistance.
Seminars in hematology 2009;46(2 Suppl 3):S27-33.
2009: Kamalesh Sankhala; Catalin Mita; Kevin Robert Kelly; Deva Mahalingam; Francis Giles; Monica Mita
The emerging safety profile of mTOR inhibitors, a novel class of anticancer agents.
Targeted oncology 2009;4(2):135-42.
2009: Kevin Robert Kelly; Ronan Swords; Deva Mahalingam; Swaminathan Padmanabhan; Francis Giles
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Targeted oncology 2009;4(2):99-105.
2009: Deva Mahalingam; Kamalesh Sankhala; Catalin Mita; Francis Giles; Monica Mita
Targeting the mTOR pathway using deforolimus in cancer therapy.
Future oncology (London, England) 2009;5(3):291-303.
2009: Francis Giles
The toxicities of modern targeted therapies: learning from the price of progress.
Targeted oncology 2009;4(2):65-6.
2009: Annelie E Abrahamsson; Ifat Geron; Jason Gotlib; Kim-Hien T Dao; Charlene F Barroga; Isabel G Newton; Francis Giles; Jeffrey A Durocher; Remi S Creusot; Mobin Karimi; Carol Jones; James L Zehnder; Armand Keating; Robert S Negrin; Irving L Weissman; Catriona H M Jamieson
Glycogen synthase kinase 3beta missplicing contributes to leukemia stem cell generation.
Proceedings of the National Academy of Sciences of the United States of America 2009;106(10):3925-9.
2009: Deva Mahalingam; Catalin Mita; Monica Mita; Steffan Nawrocki; Francis Giles
Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development.
Current problems in cancer 2009;33(2):73-111.
2009: Kevin Robert Kelly; Ronan Swords; Aoife Kilcoyne; Kamalesh Sankhala; Deva Mahalingam; Swaminathan Padmanabhan; Francis Giles
Acute lymphoblastic leukemia presenting with avascular necrosis of the elbow.
Leukemia & lymphoma 2009;50(2):297-9.
2009: Chen-Hsiung Yeh; Richard Tseng; Zhong Zhang; Jorge Cortes; Susan O'Brien; Francis Giles; Alison Hannah; Zeev Estrov; Michael Keating; Andrew Lamb; Maher Albitar
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Leukemia research 2009;33(2):212-7.
2009: Iman Jilani; C Wei; B N Bekele; Z J Zhang; M Keating; W Wierda; Alessandra Ferrajoli; Zeev Estrov; Andrew Lamb; S M O'Brien; Francis Giles; Maher Albitar
Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia.
International journal of laboratory hematology 2009;31(1):97-105.
2009: Ronan Swords; Deva Mahalingam; Swaminathan Padmanabhan; Jennifer Carew; Francis Giles
Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib.
Drug design, development and therapy 2009;3():89-101.
2009: Wanlong Ma; Andrew Lamb; Xi Zhang; Iman Jilani; Mohammad Sheikholeslami; Amber C Donahue; Farhad Ravandi; Elihu Estey; Susan O'Brien; Michael Keating; Francis Giles; Maher Albitar
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
Cancer biomarkers : section A of Disease markers 2009;5(1):51-8.
2008: Aaron D Schimmer; Susan O'Brien; Hagop Kantarjian; Joseph Brandwein; Bruce D Cheson; Mark D Minden; Karen Yee; Farhad Ravandi; Francis Giles; Andre Schuh; Vikas Gupta; Michael Andreeff; Charles Koller; Hong Chang; Suzanne Kamel-Reid; Mark Berger; Jean Viallet; Gautam Borthakur
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(24):8295-301.
2008: Tai-Sung Lee; Wanlong Ma; Xi Zhang; Francis Giles; Jorge Cortes; Hagop Kantarjian; Maher Albitar
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations.
Molecular cancer therapeutics 2008;7(12):3834-41.
2008: Monica Mita; Kamalesh Sankhala; Issam Abdel-Karim; Catalin Mita; Francis Giles
Deforolimus (AP23573) a novel mTOR inhibitor in clinical development.
Expert opinion on investigational drugs 2008;17(12):1947-54.
2008: R Swords; C O'Rafferty; Francis Giles; P Browne
Spurious elevation of the cerebrospinous fluid white cell counts in three patients receiving liposomal cytarabine as part of post-remission therapy.
Leukemia 2008;22(12):2277-8.
2008: Deva Mahalingam; Francis Giles
Challenges in developing targeted therapy for pancreatic adenocarcinoma.
Expert opinion on therapeutic targets 2008;12(11):1389-401.
2008: Steffan Nawrocki; Jennifer Carew; Kirsteen H Maclean; James F Courage; Peng Huang; Janet A Houghton; John L Cleveland; Francis Giles; David J McConkey
Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA.
Blood 2008;112(7):2917-26.
2008: Jennifer Carew; Francis Giles; Steffan Nawrocki
Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
Cancer letters 2008;269(1):7-17.
2008: Dan Jones; Deborah Thomas; C Cameron Yin; Susan O'Brien; Jorge E Cortes; Elias Jabbour; Megan Breeden; Francis Giles; Weiqiang Zhao; Hagop M Kantarjian
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors.
Cancer 2008;113(5):985-94.
2008: Catalin Mita; Monica Mita; Steffan Nawrocki; Francis Giles
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(16):5000-5.
2008: Wendy Stock; Samir D Undevia; Carol Bivins; Farhad Ravandi; Olatoyosi Odenike; Stefan Faderl; Elizabeth Rich; Gautam Borthakur; Lucy Godley; Srdan Verstovsek; Andrew Artz; William Wierda; Richard A Larson; Yanming Zhang; Jorge Cortes; Mark J Ratain; Francis Giles
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
Investigational new drugs 2008;26(4):331-8.
2008: Gautam Borthakur; Yesid Alvarado; Farhad Ravandi-Kashani; Jorge Cortes; Zeev Estrov; Stefan Faderl; Percy Ivy; Carlos Bueso-Ramos; B Nebiyou Bekele; Francis Giles
Phase 1 study of XL119, a rebeccamycin analog, in patients with refractory hematologic malignancies.
Cancer 2008;113(2):360-6.
2008: Isam A Abdel-Karim; Francis Giles
Mammalian target of rapamycin as a target in hematological malignancies.
Current problems in cancer 2008;32(4):161-77.
2008: Jennifer Carew; Steffan Nawrocki; Francis Giles; John L Cleveland
Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance.
Biologics : targets & therapy 2008;2(2):201-4.
2008: Swaminathan Padmanabhan; Saritha Ravella; Tyler J Curiel; Francis Giles
Current status of therapy for chronic myeloid leukemia: a review of drug development.
Future oncology (London, England) 2008;4(3):359-77.
2008: Hui Zhang; D Trachootham; W Lu; Jennifer Carew; Francis Giles; Michael J Keating; Ralph B Arlinghaus; P Huang
Effective killing of Gleevec-resistant CML cells with T315I mutation by a natural compound PEITC through redox-mediated mechanism.
Leukemia 2008;22(6):1191-9.
2008: Iman Jilani; Andrew Lamb; Homan Faraji; Mercedes Gorre; Jorge Cortes; Oliver G Ottmann; Kapil N Bhalla; Susan O'Brien; Francis Giles; Maher Albitar
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation.
Leukemia research 2008;32(6):936-43.
2008: David A Rizzieri; Eric Feldman; John F Dipersio; Nashat Gabrail; Wendy Stock; Roger Strair; Victor M Rivera; Maher Albitar; Camille L Bedrosian; Francis Giles
A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(9):2756-62.
2008: Tai-Sung Lee; Steven Potts; Andrew Lamb; Jorge Cortes; Francis Giles; Maher Albitar
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Cancer 2008;112(8):1744-53.
2008: David J Adams; Marit L Sandvold; Finn Myhren; Tove F Jacobsen; Francis Giles; David A Rizzieri
Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells.
Leukemia & lymphoma 2008;49(4):786-97.
2008: Wanlong Ma; Andrew Lamb; Xi Zhang; Weimin Sun; Arlene M Buller; Iman Jilani; Joyce G Schwartz; Francis Giles; Maher Albitar
Higher detection rate of JAK2 mutation using plasma.
Blood 2008;111(7):3906-7.
2008: Marcus P Kennedy; Carlos A Jimenez; John F Bruzzi; Ashwini D Mhatre; Lei Xiudong; Francis Giles; T Fanning; Rodolfo C Morice; Georgie A Eapen
Endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of lymphoma.
Thorax 2008;63(4):360-5.
2008: Iman Jilani; Andrew Lamb; Mercedes Gorre; Jorge Cortes; Oliver G Ottmann; Kapil N Bhalla; Francis Giles; Maher Albitar
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy.
Leukemia research 2008;32(4):643-9.
2008: Wanlong Ma; Andrew Lamb; Susan O'Brien; Iman Jilani; Xi Zhang; Zeev Estrov; Alessandra Ferrajoli; Michael Keating; Francis Giles; Maher Albitar
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia.
Cancer 2008;112(6):1306-12.
2008: Philipp le Coutre; Oliver G Ottmann; Francis Giles; Dong-Wook Kim; Jorge Cortes; Norbert Gattermann; Jane F Apperley; Richard A Larson; Elisabetta Abruzzese; Stephen G O'Brien; Kazimierz Kuliczkowski; Andreas Hochhaus; Francois-Xavier Mahon; Giuseppe Saglio; marco gobbi; Yok-Lam Kwong; Michele Baccarani; Timothy Hughes; giovanni martinelli; Jerald P Radich; Ming Zheng; Yaping Shou; Andrew Lamb
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia.
Blood 2008;111(4):1834-9.
2008: Francis Giles; Daniel J DeAngelo; Michele Baccarani; Michael W N Deininger; françois guilhot; Timothy Hughes; Michael J Mauro; Jerald Radich; Oliver G Ottmann; Jorge Cortes
Optimizing outcomes for patients with advanced disease in chronic myelogenous leukemia.
Seminars in oncology 2008;35(1 Suppl 1):S1-17; quiz S18-20.
2008: Srdan Verstovsek; Taghi Manshouri; Alfonso Quintás-Cardama; David Harris; Jorge Cortes; Francis Giles; Andrew Lamb; Waldemar Priebe; Zeev Estrov
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):788-96.
2008: Razelle Kurzrock; Hagop M Kantarjian; Michelle A Blascovich; Cindy Bucher; Srdan Verstovsek; John J Wright; Susan R Pilat; Jorge E Cortes; Elihu H Estey; Francis Giles; Miloslav Beran; Said M Sebti
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):509-14.
2008: Michael J Brumlik; Benjamin J Daniel; Reinhard Waehler; David T Curiel; Francis Giles; Tyler J Curiel
Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
Expert opinion on drug delivery 2008;5(1):87-103.
2008: Judith E Karp; Francis Giles; Ivana Gojo; Lawrence Morris; Jacqueline Greer; Bonny Johnson; Mya Thein; Mario Sznol; Jennifer Low
A phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders.
Leukemia research 2008;32(1):71-7.
2007: Gautam Borthakur; Edward Lin; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Francis Giles; Mary L Browning; Andrew Lamb; Michael Keating; Susan O'Brien
Low serum albumin level is associated with cytomegalovirus reactivation in patients with chronic lymphoproliferative diseases treated with alemtuzumab (Campath-1H)-based therapies.
Cancer 2007;110(11):2478-83.
2007: Jorge Cortes; Elias Jabbour; Andrew Lamb; C Cameron Yin; Jianqin Shan; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Megan Breeden; Nubia Reeves; William G Wierda; Dan Jones
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Blood 2007;110(12):4005-11.
2007: Hagop M Kantarjian; Francis Giles; Norbert Gattermann; Kapil N Bhalla; Giuliana Alimena; Francesca Palandri; Gert Ossenkoppele; Franck-Emmanuel Nicolini; Stephen G O'Brien; Mark R Litzow; Ravi Bhatia; Francisco Cervantes; Ariful Haque; Yaping Shou; Debra Resta; Aaron Weitzman; Andreas Hochhaus; Philipp le Coutre
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
Blood 2007;110(10):3540-6.
2007: Elias Jabbour; Jorge Cortes; Francis Giles; Andrew Lamb
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment.
Cancer journal (Sudbury, Mass.) 2007;13(6):357-65.
2007: Joanne Bareng; Iman Jilani; Mercedes Gorre; Andrew Lamb; Francis Giles; Alison Hannah; Maher Albitar
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry.
Leukemia & lymphoma 2007;48(11):2189-95.
2007: Elias Jabbour; Andrew Lamb; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; Stefan Faderl; Mary Ann Richie; Miloslav Beran; Francis Giles; Srdan Verstovsek
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study.
Cancer 2007;110(9):2012-8.
2007: Jorge Cortes; Alfonso Quintás-Cardama; Guillermo Garcia-Manero; Susan O'Brien; Dan Jones; Stefan Faderl; Theresa Ebarb; Francis Giles; Deborah Thomas; Andrew Lamb
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure.
Cancer 2007;110(9):2000-6.
2007: Jonathan Singer; Y Shou; Francis Giles; H M Kantarjian; Y Hsu; A S Robeva; Patricia Rae; A Weitzman; J M Meyer; M Dugan; Oliver G Ottmann
UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia.
Leukemia 2007;21(11):2311-5.
2007: Yesid Alvarado; Mary Alma Welch; Ronan Swords; John Bruzzi; Ellen Schlette; Francis Giles
Nelarabine activity in acute biphenotypic leukemia.
Leukemia research 2007;31(11):1600-3.
2007: Andres O Soriano; Hui Yang; Stefan Faderl; Zeev Estrov; Francis Giles; Farhad Ravandi; Jorge Cortes; William G Wierda; Souzanne Ouzounian; Andres Quezada; Sherry Pierce; Elihu H Estey; Jean-Pierre J Issa; Hagop M Kantarjian; Guillermo Garcia-Manero
Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome.
Blood 2007;110(7):2302-8.
2007: Francis Giles; Maher Albitar
Plasma-based testing as a new paradigm for clinical testing in hematologic diseases.
Expert review of molecular diagnostics 2007;7(5):615-23.
2007: Francis Giles
A new era for ribonucleoside reductase inhibition.
Leukemia research 2007;31(9):1163-4.
2007: Elias Jabbour; Jorge Cortes; Andrew Lamb; Sergio Giralt; Borje S Andersson; Francis Giles; Elizabeth J Shpall; Partow Kebriaei; Richard Champlin; Marcos De Lima
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Cancer 2007;110(2):340-4.
2007: Elias Jabbour; Jorge Cortes; Francis Giles; Susan O'Brien; Hagop Kantarijan
Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond.
IDrugs : the investigational drugs journal 2007;10(7):468-79.
2007: Ahmed Aribi; Carlos E Bueso-Ramos; Elihu Estey; Zeev Estrov; Susan O'Brien; Francis Giles; Stefan Faderl; Deborah Thomas; Partow Kebriaei; Guillermo Garcia-Manero; Sherry Pierce; Jorge Cortes; Andrew Lamb; Farhad Ravandi
Biphenotypic acute leukaemia: a case series.
British journal of haematology 2007;138(2):213-6.
2007: Francis Giles; Alan F List; Michael Carroll; Jorge E Cortes; Joyce Valickas; Bee-Lian Chen; Eric Masson; Christian Jacques; Dirk Laurent; Maher Albitar; Eric J Feldman; Gail J Roboz
PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia.
Leukemia research 2007;31(7):891-7.
2007: J Pan; Alfonso Quintás-Cardama; Taghi Manshouri; Francis Giles; P Lamb; Ayalew Tefferi; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Leukemia 2007;21(7):1395-404.
2007: Jennifer Carew; Steffan Nawrocki; Charissa N Kahue; Hui Zhang; Chunying Yang; Linda Chung; Janet A Houghton; Peng Huang; Francis Giles; John L Cleveland
Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance.
Blood 2007;110(1):313-22.
2007: Miloslav Beran; Sijin Wen; Yu Shen; Francesco Onida; Jaroslav Jelinek; Jorge Cortes; Francis Giles; Andrew Lamb
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System.
Leukemia & lymphoma 2007;48(6):1150-60.
2007: Francis Giles
Bendamustine and cloretazine: alkylators with sharply contrasting activity in AML.
Leukemia & lymphoma 2007;48(6):1064-6.
2007: Ronan Swords; Francis Giles
Troxacitabine in acute leukemia.
Hematology (Amsterdam, Netherlands) 2007;12(3):219-27.
2007: Elias Jabbour; Jorge E Cortes; Francis Giles; Susan O'Brien; Hagop M Kantarjian
Current and emerging treatment options in chronic myeloid leukemia.
Cancer 2007;109(11):2171-81.
2007: William G Wierda; Susan O'Brien; Xuemei Wang; Stefan Faderl; Alessandra Ferrajoli; Kim-Anh Do; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Charles Koller; Miloslav Beran; Francis Giles; Farhad Ravandi; Susan Lerner; Andrew Lamb; Michael Keating
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.
Blood 2007;109(11):4679-85.
2007: Farhad Ravandi; Iman Jilani; Elihu Estey; Andrew Lamb; A Dey; C Aguilar; C Jitkaroon; Francis Giles; Susan O'Brien; Michael Keating; Maher Albitar
Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).
Leukemia research 2007;31(6):791-7.
2007: Ronan Swords; Yesid Alvarado; Jorge Cortes; Francis Giles
Second-generation tyrosine kinase inhibitors as therapy for chronic myeloid leukemia.
Current hematologic malignancy reports 2007;2(2):83-8.
2007: Yesid Alvarado; Francis Giles
Ras as a therapeutic target in hematologic malignancies.
Expert opinion on emerging drugs 2007;12(2):271-84.
2007: Andrew Lamb; Francis Giles; Alan F List; Roger Lyons; Mikkael A Sekeres; Sherry Pierce; Robert Deuson; Joseph Leveque
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
Cancer 2007;109(9):1705-14.
2007: June M McKoy; Cara Angelotta; Charles L Bennett; Martin S Tallman; Martha Wadleigh; Andrew M Evens; Timothy M Kuzel; Steven M Trifilio; Dennis W Raisch; Jonathan Kell; Daniel J DeAngelo; Francis Giles
Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project.
Leukemia research 2007;31(5):599-604.
2007: Andrew Lamb; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Mary Beth Rios; Jianqin Shan; Francis Giles; Jorge Cortes
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
Cancer 2007;109(8):1556-60.
2007: Zhihong Zeng; Dos D. Sarbassov; Ismael Samudio; Karen W L Yee; Mark F Munsell; C Ellen Jackson; Francis Giles; David M Sabatini; Michael Andreeff; Marina Konopleva
Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.
Blood 2007;109(8):3509-12.
2007: Ronan Swords; Yesid Alvarado; Francis Giles
Novel Abl kinase inhibitors in chronic myeloid leukemia in blastic phase and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Clinical lymphoma & myeloma 2007;7 Suppl 3():S113-9.
2007: Elias Jabbour; Jorge Cortes; Susan O'Brien; Mary Beth Rios; Francis Giles; Andrew Lamb
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
Clinical lymphoma & myeloma 2007;7 Suppl 2():S51-7.
2007: Yesid Alvarado; Effrosyni Apostolidou; Ronan Swords; Francis Giles
Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia.
Expert opinion on emerging drugs 2007;12(1):165-79.
2007: Gautam Borthakur; Susan O'Brien; William G Wierda; Deborah A Thomas; Jorge E Cortes; Francis Giles; Hagop M Kantarjian; Susan Lerner; Michael J Keating
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors.
British journal of haematology 2007;136(6):800-5.
2007: Maher Albitar; M Johnson; Kim-Anh Do; A Day; Iman Jilani; S Pierce; E Estey; H Kantarjian; M Keating; S Verstovsek; S O'brien; Francis Giles
Levels of soluble HLA-I and beta2M in patients with acute myeloid leukemia and advanced myelodysplastic syndrome: association with clinical behavior and outcome of induction therapy.
Leukemia 2007;21(3):480-8.
2007: Hagop M Kantarjian; Francis Giles; Alfonso Quintás-Cardama; Jorge Cortes
Important therapeutic targets in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1089-97.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Farhad Ravandi; Francis Giles; Deborah Thomas; William G Wierda; Jorge Cortes
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
Leukemia & lymphoma 2007;48(2):283-9.
2007: Wanlong Ma; Richard Tseng; Mercedes Gorre; Iman Jilani; Michael Keating; Andrew Lamb; Jorge Cortes; Susan O'Brien; Francis Giles; Maher Albitar
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia.
Haematologica 2007;92(2):170-5.
2007: Francis Giles; Gautam Borthakur; Farhad Ravandi; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Sherry Pierce; Maher Albitar; Jorge Cortes; Andrew Lamb
The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia.
British journal of haematology 2007;136(4):624-7.
2007: T Haritunians; A Mori; James O'Kelly; Quang T Luong; Francis Giles; H Phillip Koeffler
Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma.
Leukemia 2007;21(2):333-9.
2007: Maher Albitar; Julie M Vose; Marcella M Johnson; Kim-Anh Do; Amanda Day; Iman Jilani; Andrew Lamb; Michael Keating; Susan M O'Brien; Srdan Verstovsek; James O Armitage; Francis Giles
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Leukemia research 2007;31(2):139-45.
2007: Alfonso Quintás-Cardama; Andrew Lamb; Guillermo Garcia-Manero; Susan O'Brien; Stefan Faderl; Zeev Estrov; Francis Giles; Anthony J Murgo; Nakia Ladie; Srdan Verstovsek; Jorge Cortes
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
Cancer 2007;109(2):248-55.
2007: Francis Giles; Jorge Cortes; Dan Jones; Donald Bergstrom; Andrew Lamb; Steven J Freedman
MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation.
Blood 2007;109(2):500-2.
2007: Alfonso Quintas-Cardama; Andrew Lamb; Dan Jones; Claude Nicaise; Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
Blood 2007;109(2):497-9.
2007: Effrosyni Apostolidou; Ronan Swords; Yesid Alvarado; Francis Giles
Treatment of acute lymphoblastic leukaemia : a new era.
Drugs 2007;67(15):2153-71.
2007: Ronan Swords; John Bruzzi; Francis Giles
Recent advances in the diagnosis and therapy of Richter's syndrome.
Medical oncology (Northwood, London, England) 2007;24(1):17-32.
2007: Ronan Swords; Francis Giles
Hairy cell leukemia.
Medical oncology (Northwood, London, England) 2007;24(1):7-15.
2007: Julie M Vose; Amit Panwalkar; Robert Belanger; Bertrand Coiffier; Michele Baccarani; Stephanie A Gregory; Thierry Facon; Renato Fanin; Dolores Caballero; Dina Ben-Yehuda; Francis Giles
A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma.
Leukemia & lymphoma 2007;48(1):39-45.
2007: Elias Jabbour; Jorge Cortes; Susan O'Brien; Francis Giles; Andrew Lamb
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance.
Seminars in hematology 2007;44(1 Suppl 1):S25-31.
2007: Gail J Roboz; Francis Giles; Ellen K Ritchie; Sandra Allen-Bard; Tania J Curcio; Meredith A Wilkes; S Lani Park; Hagop M Kantarjian; Stefan Faderl; Farhad Ravandi; Michael J Kelner; Eric J Feldman
Phase I/II study of continuous-infusion troxacitabine in refractory acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):10-5.
2007: Francis Giles; David A Rizzieri; Judith E Karp; Norbert Vey; Farhad Ravandi; Stefan Faderl; Khuda Dad Khan; Gregor Verhoef; Pierre W Wijermans; Anjali Advani; Gail J Roboz; Andrew Lamb; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Ghulam Mufti; Susan O'Brien
Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(1):25-31.
2007: Jingxuan Pan; Alfonso Quintás-Cardama; Hagop M Kantarjian; Cem Akin; Taghi Manshouri; Peter Lamb; Jorge E Cortes; Ayalew Tefferi; Francis Giles; Srdan Verstovsek
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation.
Blood 2007;109(1):315-22.
2007: Andrew Lamb; Yasuhiro Oki; Guillermo Garcia-Manero; Xuelin Huang; Susan O'Brien; Jorge Cortes; Stefan Faderl; Carlos E Bueso-Ramos; Farhad Ravandi; Zeev Estrov; Alessandra Ferrajoli; William Wierda; Jianqin Shan; Jan Davis; Francis Giles; Hussain I Saba; Jean-Pierre J Issa
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Blood 2007;109(1):52-7.
2006: Hagop M Kantarjian; Moshe Talpaz; Francis Giles; Susan O'Brien; Jorge Cortes
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance.
Annals of internal medicine 2006;145(12):913-23.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Nichole Perez; Farhad Ravandi-Kashani; Miloslav Beran; Emil J Freireich; Andrew Lamb
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Hematological oncology 2006;24(4):181-8.
2006: Srdan Verstovsek; Francis Giles; Alfonso Quintás-Cardama; Taghi Manshouri; Ly Huynh; Paul Manley; Jorge Cortes; Ayalew Tefferi; Andrew Lamb
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells.
Leukemia research 2006;30(12):1499-505.
2006: Francis Giles
FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Leukemia research 2006;30(12):1469-70.
2006: Francis Giles; Srdan Verstovsek; Stefan Faderl; Norbert Vey; Judith E Karp; Gail J Roboz; Khuda Dad Khan; Maureen Cooper; Syed Fazl Ali Bilgrami; Augustin Ferrant; S M G J Daenen; Verena Karsten; Ann Cahill; Maher Albitar; Andrew Lamb; Susan O'Brien; Eric Feldman
A phase II study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients with very high risk relapsed acute myeloid leukemia.
Leukemia research 2006;30(12):1591-5.
2006: Mark Levis; Patrick Brown; B Douglas Smith; Adam Stine; Rosalyn Pham; Richard M Stone; Daniel J DeAngelo; Ilene Galinsky; Francis Giles; Elihu Estey; Andrew Lamb; Pamela Cohen; Yanfeng Wang; Johannes Roesel; Judith E Karp; Donald Small
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors.
Blood 2006;108(10):3477-83.
2006: W Ma; Andrew Lamb; Iman Jilani; Mercedes Gorre; Kapil N Bhalla; Oliver G Ottmann; Francis Giles; Maher Albitar
Heterogeneity in detecting Abl kinase mutations and better sensitivity using circulating plasma RNA.
Leukemia 2006;20(11):1989-91.
2006: Srdan Verstovsek; Cem Akin; Taghi Manshouri; Alfonso Quintás-Cardama; Ly Huynh; Paul Manley; Ayalew Tefferi; Jorge Cortes; Francis Giles; Andrew Lamb
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit.
Leukemia research 2006;30(11):1365-70.
2006: Ronan Swords; Effrosyni Apostolidou; Francis Giles
Troxacitabine in leukemia.
Hematology (Amsterdam, Netherlands) 2006;11(5):321-9.
2006: Iman Jilani; M Keating; A Day; W William; Andrew Lamb; S O'brien; Francis Giles; Maher Albitar
Simplified sensitive method for the detection of B-cell clonality in lymphoid malignancies.
Clinical and laboratory haematology 2006;28(5):325-31.
2006: Alfonso Quintas-Cardama; Andrew Lamb; Susan O'Brien; Elias Jabbour; Francis Giles; Farhad Ravandi; Stefan Faderl; Sherry Pierce; Jianqin Shan; Srdan Verstovsek; Jorge Cortes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cancer 2006;107(7):1525-9.
2006: Alfonso Quintas-Cardama; Ahmed Aribi; Jorge Cortes; Francis Giles; Andrew Lamb; Srdan Verstovsek
Novel approaches in the treatment of systemic mastocytosis.
Cancer 2006;107(7):1429-39.
2006: Elias Jabbour; Andrew Lamb; Dan Jones; Moshe Talpaz; Nebiyou Bekele; Susan O'Brien; Xian Zhou; Rajyalakshmi Luthra; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Srdan Verstovsek; Jorge Cortes
Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate.
Leukemia 2006;20(10):1767-73.
2006: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Daniel Jones; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Farhad Ravandi; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia.
Blood 2006;108(6):1835-40.
2006: Cecilia Arana-Yi; Alfonso Quintás-Cardama; Francis Giles; Deborah Thomas; Antonio Carrasco-Yalan; Jorge Cortes; Andrew Lamb; Srdan Verstovsek
Advances in the therapy of chronic idiopathic myelofibrosis.
The oncologist 2006;11(8):929-43.
2006: Karen W L Yee; Zhihong Zeng; Marina Konopleva; Srdan Verstovsek; Farhad Ravandi; Alessandra Ferrajoli; Deborah Thomas; William G Wierda; Efrosyni Apostolidou; Maher Albitar; Susan O'Brien; Michael Andreeff; Francis Giles
Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(17):5165-73.
2006: Mihaela Onciu; Ellen Schlette; Yinmei Zhou; Susana C Raimondi; Francis Giles; Hagop M Kantarjian; L Jeffrey Medeiros; Raul C Ribeiro; Ching-Hon Pui; John T Sandlund
Secondary chromosomal abnormalities predict outcome in pediatric and adult high-stage Burkitt lymphoma.
Cancer 2006;107(5):1084-92.
2006: Nada Orsolic; Mirna Golemovic; Alfonso Quintás-Cardama; Barbara Scappini; Taghi Manshouri; Joya Chandra; Ivan Basic; Francis Giles; Andrew Lamb; Srdan Verstovsek
Adaphostin has significant and selective activity against chronic and acute myeloid leukemia cells.
Cancer science 2006;97(9):952-60.
2006: A Quintás-Cardama; L V Abruzzo; Francis Giles; J Jorgensen; J Cortes; J E Sarriera; H Kantarjian; S Verstovsek
A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome.
Leukemia 2006;20(9):1638-40.
2006: Ayalew Tefferi; Jorge Cortes; Srdan Verstovsek; Ruben A Mesa; Deborah Thomas; Terra L Lasho; William J Hogan; Mark R Litzow; Jacob B Allred; Dan Jones; Catriona Byrne; Jerome B Zeldis; Rhett P Ketterling; Rebecca F McClure; Francis Giles; Hagop M Kantarjian
Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Blood 2006;108(4):1158-64.
2006: Elias Jabbour; Jorge Cortes; Hagop M Kantarjian; Sergio Giralt; Dan Jones; Roy Jones; Francis Giles; Borje S Andersson; Richard Champlin; Marcos De Lima
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Blood 2006;108(4):1421-3.
2006: Francis Giles; Thomas Fischer; Jorge Cortes; Guillermo Garcia-Manero; Joachim Beck; Farhad Ravandi; Eric Masson; Patricia Rae; Glen Laird; Sunil Sharma; Andrew Lamb; Margaret Dugan; Maher Albitar; Kapil N Bhalla
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(15):4628-35.
2006: W Ma; Andrew Lamb; Srdan Verstovsek; Iman Jilani; Mercedes Gorre; Francis Giles; J Cortes; S O'Brien; M Keating; Maher Albitar
Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour.
British journal of haematology 2006;134(3):341-3.
2006: Charles Koller; B Nebiyou Bekele; Xian Zhou; Charles Park; Zeev Estrov; Susan O'Brien; Michael Keating; Iman Jilani; Francis Giles; Hagop M Kantarjian; Maher Albitar
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
Blood 2006;108(3):1001-6.
2006: Mohammad Sheikholeslami; I Jilani; M Keating; J Uyeji; K Chen; H Kantarjian; S O'Brien; Francis Giles; M Albitar
Variations in the detection of ZAP-70 in chronic lymphocytic leukemia: Comparison with IgV(H) mutation analysis.
Cytometry. Part B, Clinical cytometry 2006;70(4):270-5.
2006: Warren C Fiskus; Michael Pranpat; Purva Bali; Maria Balasis; Sandhya Kumaraswamy; Sandhya Boyapalle; Kathy Rocha; Jie Wu; Francis Giles; Paul W Manley; Peter Atadja; Kapil N Bhalla
Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against Bcr-Abl-expressing human leukemia cells.
Blood 2006;108(2):645-52.
2006: Francis Giles; Srdan Verstovsek; Guillermo Garcia-Manero; Deborah Thomas; Farhad Ravandi; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Elias Jabbour; Jianqin Shan; Susan O'Brien; Maher Albitar; Andrew Lamb
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse.
British journal of haematology 2006;134(1):58-60.
2006: Joseph Moore; Karen Seiter; Jonathan E Kolitz; Wendy Stock; Francis Giles; Matt Kalaycio; David Zenk; Guido Marcucci
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse.
Leukemia research 2006;30(7):777-83.
2006: Karen W L Yee; Jorge Cortes; Alessandra Ferrajoli; Guillermo Garcia-Manero; Srdan Verstovsek; William G Wierda; Deborah Thomas; Stefan Faderl; Ivan King; Susan M O'Brien; Sima Jeha; Michael Andreeff; Ann Cahill; Mario Sznol; Francis Giles
Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome.
Leukemia research 2006;30(7):813-22.
2006: Stefan Faderl; Srdan Verstovsek; Jorge Cortes; Farhad Ravandi; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Susan O'Brien; Charles Koller; Francis Giles; William G Wierda; Monica Kwari; Hagop M Kantarjian
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older.
Blood 2006;108(1):45-51.
2006: Francis Giles; William T Bellamy; Zeev Estrov; Susan M O'Brien; Srdan Verstovsek; Farhad Ravandi; Miloslav Beran; Paul Bycott; Yazdi K Pithavala; Heidi M Steinfeldt; Steven D Reich; Alan F List; Karen W L Yee
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Leukemia research 2006;30(7):801-11.
2006: Andrew Lamb; Francis Giles; Lydia Wunderle; Kapil N Bhalla; Susan O'Brien; Barbara Wassmann; Chiaki Tanaka; Paul Manley; Patricia Rae; William Mietlowski; Kathy Bochinski; Andreas Hochhaus; James D Griffin; Dieter Hoelzer; Maher Albitar; Margaret Dugan; Jorge Cortes; Leila Alland; Oliver G Ottmann
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
The New England journal of medicine 2006;354(24):2542-51.
2006: Farhad Ravandi; Jeffrey L Jorgensen; Susan M O'Brien; Srdan Verstovsek; Charles Koller; Stefan Faderl; Francis Giles; Alessandra Ferrajoli; William G Wierda; Shirley Odinga; Xuelin Huang; Deborah A Thomas; Emil J Freireich; Dan Jones; Michael J Keating; Hagop M Kantarjian
Eradication of minimal residual disease in hairy cell leukemia.
Blood 2006;107(12):4658-62.
2006: Alfonso Quintás-Cardama; Hagop M Kantarjian; Francis Giles; Srdan Verstovsek
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders.
Seminars in thrombosis and hemostasis 2006;32(4 Pt 2):409-16.
2006: Francis Giles
Clone wars in CML.
Leukemia 2006;20(6):939-40.
2006: W Ma; Iman Jilani; Mercedes Gorre; M Keating; H Chan; R Tseng; Andrew Lamb; S O'Brien; Francis Giles; Maher Albitar
Plasma as a source of mRNA for determining IgV(H) mutation status in patients with chronic lymphocytic leukaemia.
British journal of haematology 2006;133(6):690-2.
2006: Gail J Roboz; Francis Giles; Alan F List; Jorge E Cortes; R Carlin; M Kowalski; S Bilic; Eric Masson; M Rosamilia; Michael W Schuster; D Laurent; Eric J Feldman
Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
Leukemia 2006;20(6):952-7.
2006: Apostolia-Maria Tsimberidou; Susan O'Brien; Issa Khouri; Francis Giles; Hagop M Kantarjian; Richard Champlin; Sijin Wen; Kim-Anh Do; Susan C Smith; Susan Lerner; Emil J Freireich; Michael J Keating
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(15):2343-51.
2006: Barry D Hock; Judith L McKenzie; Nigel W Patton; Mark T Drayson; Karen Taylor; Chris Wakeman; Andrew Lamb; Francis Giles; Maher Albitar
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies.
Cancer 2006;106(10):2148-57.
2006: Karen W L Yee; Sharon R Hymes; Lior Heller; Victor G Prieto; Mary Alma Welch; Francis Giles
Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: case report and review of the literature.
Leukemia & lymphoma 2006;47(5):926-9.
2006: Deborah A Thomas; Francis Giles; Maher Albitar; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Susan M O'Brien; Guillermo Garcia-Manero; Michael J Keating; Sherry Pierce; Jerome B Zeldis; Hagop M Kantarjian
Thalidomide therapy for myelofibrosis with myeloid metaplasia.
Cancer 2006;106(9):1974-84.
2006: Carlton K K Lee; Eric K Rowinsky; Jing Li; Francis Giles; Malcolm J Moore; Manuel Hidalgo; Edmund Capparelli; Jacques Jolivet; Sharyn D Baker
Population pharmacokinetics of troxacitabine, a novel dioxolane nucleoside analogue.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2158-65.
2006: Maher Albitar; Steven Potts; Francis Giles; Susan O'Brien; Michael Keating; Deborah Thomas; Charlotte Clarke; Iman Jilani; Christine Aguilar; Elihu Estey; Andrew Lamb
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia.
Cancer 2006;106(7):1587-94.
2006: Deborah A Thomas; Stefan Faderl; Susan O'Brien; Carlos E Bueso-Ramos; Jorge Cortes; Guillermo Garcia-Manero; Francis Giles; Srdan Verstovsek; William G Wierda; Sherry A Pierce; Jianqin Shan; Mark Brandt; Fredrick B Hagemeister; Michael J Keating; Fernando Cabanillas; Andrew Lamb
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
Cancer 2006;106(7):1569-80.
2006: Elias Jabbour; Francis Giles
New agents in myelodysplastic syndromes.
Current hematologic malignancy reports 2006;1(1):25-33.
2006: Ahmed Aribi; Farhad Ravandi; Francis Giles
Novel agents in acute myeloid leukemia.
Cancer journal (Sudbury, Mass.) 2006;12(2):77-91.
2006: Norbert Vey; Francis Giles
Cloretazine for the treatment of acute myeloid leukemia.
Expert review of anticancer therapy 2006;6(3):321-8.
2006: Patricia Ault; Andrew Lamb; Susan O'Brien; Stefan Faderl; Miloslav Beran; Mary Beth Rios; Charles Koller; Francis Giles; Michael Keating; Moshe Talpaz; Jorge Cortes
Pregnancy among patients with chronic myeloid leukemia treated with imatinib.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1204-8.
2006: Andrew Lamb; Miloslav Beran; Jorge Cortes; Susan O'Brien; Francis Giles; Sherry Pierce; Jianqin Shan; William Plunkett; Michael Keating; Elihu Estey
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome.
Cancer 2006;106(5):1099-109.
2006: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Elias Jabbour; Guillermo Garcia-Manero; William G Wierda; Sherry Pierce; Jianqin Shan; Elihu Estey
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome.
Cancer 2006;106(5):1090-8.
2006: Apostolia-Maria Tsimberidou; Francis Giles; Elihu Estey; Susan O'Brien; Michael J Keating; Hagop M Kantarjian
The role of gemtuzumab ozogamicin in acute leukaemia therapy.
British journal of haematology 2006;132(4):398-409.
2006: Yasuhiro Oki; Hagop M Kantarjian; Xian Zhou; Jorge Cortes; Stefan Faderl; Srdan Verstovsek; Susan O'Brien; Charles Koller; Miloslav Beran; B Nebiyou Bekele; Sherry Pierce; Deborah Thomas; Farhad Ravandi; William G Wierda; Francis Giles; Alessandra Ferrajoli; Elias Jabbour; Michael J Keating; Carlos E Bueso-Ramos; Elihu Estey; Guillermo Garcia-Manero
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.
Blood 2006;107(3):880-4.
2006: William G Wierda; Susan O'Brien; Stefan Faderl; Alessandra Ferrajoli; Xuemei Wang; Kim-Anh Do; Guillermo Garcia-Manero; Deborah Thomas; Jorge Cortes; Farhad Ravandi-Kashani; Francis Giles; Susan Lerner; Andrew Lamb; Michael Keating
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens.
Cancer 2006;106(2):337-45.
2006: Gautam Borthakur; Andrew Lamb; George Q Daley; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Mary Sugrue; Jorge Cortes
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.
Cancer 2006;106(2):346-52.
2006: Gloria N Mattiuzzi; Gladys Alvarado; Francis Giles; Luis Ostrosky-Zeichner; Jorge Cortes; Susan O'Brien; Srdan Verstovsek; Stefan Faderl; Xian Zhou; Issam I Raad; B Nebiyou Bekele; Gerhard J Leitz; Ivonne Lopez-Roman; Elihu H Estey
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies.
Antimicrobial agents and chemotherapy 2006;50(1):143-7.
2006: Deborah A Thomas; Andreas H Sarris; Jorge Cortes; Stefan Faderl; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Maria A Rodriguez; Fernando Cabanillas; Andrew Lamb
Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia.
Cancer 2006;106(1):120-7.
2006: Florian Heidel; Fian K Solem; Frank Breitenbuecher; Daniel B Lipka; Stefan Kasper; M H Thiede; Christian Brandts; Hubert Serve; Johannes Roesel; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary J Schiller; Stephen D Nimer; Richard M Stone; Yanfeng Wang; Thomas Kindler; Pamela S Cohen; Christoph Huber; Thomas Fischer
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Blood 2006;107(1):293-300.
2005: Stefan Faderl; Kim-Anh Do; Marcella M Johnson; Michael Keating; Susan O'Brien; Iman Jilani; Alessandra Ferrajoli; Farhad Ravandi-Kashani; Christine Aguilar; Amanda Dey; Deborah A Thomas; Francis Giles; Hagop M Kantarjian; Maher Albitar
Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia.
Blood 2005;106(13):4303-7.
2005: Karen W L Yee; Elias Jabbour; Hagop M Kantarjian; Francis Giles
Clinical experience with decitabine in North American patients with myelodysplastic syndrome.
Annals of hematology 2005;84 Suppl 1():18-24.
2005: Rui-Hua Xu; Helene Pelicano; Hui Zhang; Francis Giles; Michael J Keating; P Huang
Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells.
Leukemia 2005;19(12):2153-8.
2005: Farhad Ravandi; Susan O'Brien; Dan Jones; Susan Lerner; Stefan Faderl; Alessandra Ferrajoli; William G Wierda; Guillermo Garcia-Manero; Deborah Thomas; Charles Koller; Srdan Verstovsek; Francis Giles; Jorge Cortes; Marco Herling; Andrew Lamb; Michael Keating
T-cell prolymphocytic leukemia: a single-institution experience.
Clinical lymphoma & myeloma 2005;6(3):234-9.
2005: Susan O'Brien; Maher Albitar; Francis Giles
Monoclonal antibodies in the treatment of leukemia.
Current molecular medicine 2005;5(7):663-75.
2005: Francis Giles; Maher Albitar
Mammalian target of rapamycin as a therapeutic target in leukemia.
Current molecular medicine 2005;5(7):653-61.
2005: Francis Giles; Jorge E Cortes; Hagop M Kantarjian
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.
Current molecular medicine 2005;5(7):615-23.
2005: Francis Giles
Targeted therapy in hematologic maligancies--progress made, lessons learned?
Current molecular medicine 2005;5(7):607.
2005: Francis Giles; Srdan Verstovsek; Deborah Thomas; Stanton Gerson; Jorge Cortes; Stefan Faderl; Alessandra Ferrajoli; Farhad Ravandi; Steven M Kornblau; Guillermo Garcia-Manero; Elias Jabbour; Susan O'Brien; Verena Karsten; Ann Cahill; Karen Yee; Maher Albitar; Mario Sznol; Andrew Lamb
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(21):7817-24.
2005: Gloria N Mattiuzzi; Francis Giles
Management of intracranial fungal infections in patients with haematological malignancies.
British journal of haematology 2005;131(3):287-300.
2005: Karen W L Yee; Anne Hagey; Srdan Verstovsek; Jorge Cortes; Guillermo Garcia-Manero; Susan M O'Brien; Stefan Faderl; Deborah Thomas; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Maher Albitar; Evelyn McKeegan; David R Grimm; Toby Mueller; Rhonda R Holley-Shanks; Leonardo Sahelijo; Gary B Gordon; Hagop M Kantarjian; Francis Giles
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6615-24.
2005: Srdan Verstovsek; Mirna Golemovic; Andrew Lamb; Taghi Manshouri; Zeev Estrov; Paul Manley; Tong Sun; Ralph B Arlinghaus; Leila Alland; Margaret Dugan; Jorge Cortes; Francis Giles; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells.
Cancer 2005;104(6):1230-6.
2005: Hesham M Amin; Y Yang; Yu Shen; Elihu H Estey; Francis Giles; Sherry A Pierce; Hagop M Kantarjian; Susan M O'Brien; Iman Jilani; Maher Albitar
Having a higher blast percentage in circulation than bone marrow: clinical implications in myelodysplastic syndrome and acute lymphoid and myeloid leukemias.
Leukemia 2005;19(9):1567-72.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; William G Wierda; Mary Beth Rios; Jianqin Shan; Jorge Cortes
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy.
Cancer 2005;104(4):777-80.
2005: Elias Jabbour; Srdan Verstovsek; Francis Giles; Varsha Gandhi; Jorge Cortes; Susan O'Brien; William Plunkett; Guillermo Garcia-Manero; C Ellen Jackson; Andrew Lamb; Michael Andreeff
2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.
Cancer 2005;104(3):541-6.
2005: Francis Giles; Susan O'Brien; Jorge Cortes; Srdan Verstovsek; Carlos E Bueso-Ramos; Jianqin Shan; Sherry Pierce; Guillermo Garcia-Manero; Michael Keating; Andrew Lamb
Outcome of patients with acute myelogenous leukemia after second salvage therapy.
Cancer 2005;104(3):547-54.
2005: Hagop M Kantarjian; Carlos E Bueso-Ramos; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianqin Shan; Jorge Cortes
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy.
Leukemia & lymphoma 2005;46(7):993-7.
2005: Mirna Golemovic; Srdan Verstovsek; Francis Giles; Jorge Cortes; Taghi Manshouri; Paul W Manley; Jürgen Mestan; Margaret Dugan; Leila Alland; James D Griffin; Ralph B Arlinghaus; Tong Sun; Andrew Lamb; Miloslav Beran
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13):4941-7.
2005: Michael J Keating; Susan O'Brien; Maher Albitar; Susan Lerner; William Plunkett; Francis Giles; Michael Andreeff; Jorge Cortes; Stefan Faderl; Deborah Thomas; Charles Koller; William G Wierda; Michelle A Detry; Alice Lynn; Andrew Lamb
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4079-88.
2005: William G Wierda; Susan O'Brien; Sijin Wen; Stefan Faderl; Guillermo Garcia-Manero; Deborah Thomas; Kim-Anh Do; Jorge Cortes; Charles Koller; Miloslav Beran; Alessandra Ferrajoli; Francis Giles; Susan Lerner; Maher Albitar; Andrew Lamb; Michael Keating
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4070-8.
2005: Rashid Saba; Elias Jabbour; Francis Giles; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Emil J Freireich; Guillermo Garcia-Manero; Andrew Lamb; Srdan Verstovsek
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986.
Cancer 2005;103(12):2551-7.
2005: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Stefan Faderl; Srdan Verstovsek; Deborah Thomas; Guillermo Garcia-Manero; William G Wierda; Alessandra Ferrajoli; Steven M Kornblau; Gloria N Mattiuzzi; Apostolia-Maria Tsimberidou; Maher Albitar; Susan M O'Brien; Elihu Estey
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes.
Leukemia research 2005;29(6):649-52.
2005: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Jianqin Shan; Mary Beth Rios; Richard Champlin; Marcos De Lima; Jorge Cortes
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience.
Cancer 2005;103(10):2099-108.
2005: Karen W L Yee; Susan M O'Brien; Francis Giles
Richter's syndrome: biology and therapy.
Cancer journal (Sudbury, Mass.) 2005;11(3):161-74.
2005: Jorge Cortes; Moshe Talpaz; Susan O'Brien; Dan Jones; Rajyalakshmi Luthra; Jianqin Shan; Francis Giles; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Mary Beth Rios; Andrew Lamb
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3425-32.
2005: Elias J Jabbour; Francis Giles
New agents in myelodysplastic syndromes.
Current hematology reports 2005;4(3):191-9.
2005: Jorge Cortes; Stefan Faderl; Elihu Estey; Razelle Kurzrock; Deborah Thomas; Miloslav Beran; Guillermo Garcia-Manero; Alessandra Ferrajoli; Francis Giles; Charles Koller; Susan O'Brien; John Wright; Stephen A Bai; Andrew Lamb
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(12):2805-12.
2005: Stefan Faderl; Varsha Gandhi; Susan O'Brien; Peter L Bonate; Jorge Cortes; Elihu Estey; Miloslav Beran; William G Wierda; Guillermo Garcia-Manero; Alessandra Ferrajoli; Zeev Estrov; Francis Giles; Min Du; Monica Kwari; Michael Keating; William Plunkett; Andrew Lamb
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Blood 2005;105(3):940-7.
2005: Apostolia-Maria Tsimberidou; Francis Giles; Issa Khouri; Carlos E Bueso-Ramos; Susan R Pilat; Deborah A Thomas; Jorge Cortes; Razelle Kurzrock
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(1):139-45.
2005: Bryan T. J. Hennessy; Deborah A Thomas; Francis Giles; Andrew Lamb; Srdan Verstovsek
New approaches in the treatment of myelofibrosis.
Cancer 2005;103(1):32-43.
2005: Francis Giles
Gemtuzumab ozogamicin: a component of induction therapy in AML?
Leukemia research 2005;29(1):1-2.
2005: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; Elihu Estey; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary Schiller; Virginia Klimek; Stephen D Nimer; Alois Gratwohl; Chunaram Choudhary; Constan Mueller-Tidow; Hubert Serve; Harald Gschaidmeier; Pamela S Cohen; Christoph Huber; Thomas Fischer
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Andrew Lamb; Deborah Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Sima Jeha; Carlos E Bueso-Ramos; Sherry Pierce; Jianqin Shan; Charles Koller; Miloslav Beran; Michael Keating; Emil J Freireich
Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Cancer 2004;101(12):2788-801.
2004: Iman Jilani; Michael Keating; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Maher Albitar
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
Leukemia research 2004;28(12):1255-62.
2004: Bryan T. J. Hennessy; Francis Giles; Jorge Cortes; Susan O'Brien; Alessandra Ferrajoli; Gladys Ossa; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Srdan Verstovsek
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
American journal of hematology 2004;77(3):209-14.
2004: X Sun; H M Amin; E J Freireich; M J Keating; H M Kantarjian; C A Koller; S M O'Brien; Francis Giles; M Albitar
Hairy cell leukemia with large cells: long disease course with adequate response to therapy.
Leukemia 2004;18(11):1912-4.
2004: Zhiqing Wang; Yana Zhang; Arabinda Mandal; Jian Zhang; Francis Giles; John C Herr; Seah H Lim
The spermatozoa protein, SLLP1, is a novel cancer-testis antigen in hematologic malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(19):6544-50.
2004: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Rajyalakshmi Luthra; Francis Giles; Srdan Verstovsek; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Dan Jones; Moshe Talpaz
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha.
Blood 2004;104(7):1979-88.
2004: Deborah A Thomas; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Charles Koller; Miloslav Beran; Sherry Pierce; Chul Ha; Fernando Cabanillas; Michael J Keating; Andrew Lamb
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
Blood 2004;104(6):1624-30.
2004: Maher Albitar; Kim-Anh Do; Marcella M Johnson; Francis Giles; Iman Jilani; Susan O'Brien; Jorge Cortes; Deborah Thomas; Laura Rassenti; Thomas Kipps; Hagop M Kantarjian; Michael Keating
Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
Cancer 2004;101(5):999-1008.
2004: Apostolia-Maria Tsimberidou; Elihu Estey; Gary J Whitman; Mark J Dryden; Suresh Ratnam; Sherry Pierce; Stefan Faderl; Francis Giles; Hagop M Kantarjian; Guillermo Garcia-Manero
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies.
Leukemia research 2004;28(9):991-4.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Madeleine Duvic; Razelle Kurzrock
Pilot study of etanercept in patients with relapsed cutaneous T-cell lymphomas.
Journal of the American Academy of Dermatology 2004;51(2):200-4.
2004: Carlos E Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; L Jeffrey Medeiros; Andrew Lamb
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia.
Cancer 2004;101(2):332-6.
2004: Karen W L Yee; Susan M O'Brien; Francis Giles
An update on the management of chronic lymphocytic leukaemia.
Expert opinion on pharmacotherapy 2004;5(7):1535-54.
2004: Srdan Verstovsek; Francis Giles; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia.
Leukemia research 2004;28(7):707-11.
2004: Anne-Marie O'Farrell; Helene A Yuen; Beverly D Smolich; Alison L Hannah; Sharianne G Louie; Weiru Hong; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Judith E Karp; Maher Albitar; Julie M Cherrington; Francis Giles
Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia.
Leukemia research 2004;28(7):679-89.
2004: Apostolia-Maria Tsimberidou; Michael J Keating; Francis Giles; William G Wierda; Alessandra Ferrajoli; Susan Lerner; Miloslav Beran; Michael Andreeff; Hagop M Kantarjian; Susan O'Brien
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
Cancer 2004;100(12):2583-91.
2004: Deborah A Thomas; Stefan Faderl; Jorge Cortes; Susan O'Brien; Francis Giles; Steven M Kornblau; Guillermo Garcia-Manero; Michael J Keating; Michael Andreeff; Sima Jeha; Miloslav Beran; Srdan Verstovsek; Sherry Pierce; Laurie Letvak; August Salvado; Richard Champlin; Moshe Talpaz; Andrew Lamb
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate.
Blood 2004;103(12):4396-407.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien
Accelerated and blastic phases of chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):753-74, xii.
2004: Jorge E Cortes; Susan M O'Brien; Francis Giles; Ricardo H Alvarez; Moshe Talpaz; Hagop M Kantarjian
Investigational strategies in chronic myelogenous leukemia.
Hematology/oncology clinics of North America 2004;18(3):619-39, ix.
2004: Dawn E Colburn; Francis Giles; Debra Oladovich; Judith A Smith
In vitro evaluation of cytochrome P450-mediated drug interactions between cytarabine, idarubicin, itraconazole and caspofungin.
Hematology (Amsterdam, Netherlands) 2004;9(3):217-21.
2004: Jorge Cortes; Susan O'Brien; Alfonso Quintas; Francis Giles; Jianquin Shan; Mary Beth Rios; Moshe Talpaz; Andrew Lamb
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase.
Cancer 2004;100(11):2396-402.
2004: Patricia Ault; Andrew Lamb; Mary Alma Welch; Francis Giles; Mary Beth Rios; Jorge Cortes
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia.
Leukemia research 2004;28(6):613-8.
2004: Francis Giles; Julie M Vose; Kim-Anh Do; Marcella M Johnson; Taghi Manshouri; Gregory Bociek; Philip J Bierman; Susan M O'Brien; Hagop M Kantarjian; James O Armitage; Maher Albitar
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma.
Leukemia research 2004;28(6):595-604.
2004: Francis Giles; Roberto Rodriguez; Daniel Weisdorf; John R Wingard; Paul J Martin; Thomas R Fleming; Stuart L Goldberg; Elias J Anaissie; Brian J Bolwell; Nelson J Chao; Thomas C Shea; Mark M Brunvand; William Vaughan; Finn Petersen; Mark Schubert; Hillard M Lazarus; Richard T Maziarz; Margarida Silverman; Roy A Beveridge; Rebecca Redman; Janis G Pulliam; Patricia Devitt-Risse; Henry J Fuchs; David D Hurd
A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy.
Leukemia research 2004;28(6):559-65.
2004: Jorge Cortes; Deborah Thomas; Charles Koller; Francis Giles; Elihu Estey; Stefan Faderl; Guillermo Garcia-Manero; David J McConkey; Stacey Ruiz; Gira Patel; Roberto Guerciolini; John Wright; Andrew Lamb
Phase I study of bortezomib in refractory or relapsed acute leukemias.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3371-6.
2004: Yupo Ma; Adnan Mansour; B Nebiyou Bekele; Xian Zhou; Michael J Keating; Susan O'Brien; Francis Giles; Maher Albitar
The clinical significance of large cells in bone marrow in patients with chronic lymphocytic leukemia.
Cancer 2004;100(10):2167-75.
2004: B Douglas Smith; Mark Levis; Miloslav Beran; Francis Giles; Andrew Lamb; Karin Berg; KATHLEEN MURPHY; Tianna Dauses; Jeffrey Allebach; Donald Small
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia.
Blood 2004;103(10):3669-76.
2004: Francis Giles; Deborah Thomas; Guillermo Garcia-Manero; Stefan Faderl; Jorge Cortes; Srdan Verstovsek; Alessandra Ferrajoli; Sima Jeha; Miloslav Beran; Charles Koller; Michael Andreeff; Ann Cahill; Caroline Clairmont; Mario Sznol; Andrew Lamb
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(9):2908-17.
2004: Qinglong Hu; Amanda L Dey; Ying Yang; Yu Shen; Iman Jilani; Elihu H Estey; Hagop M Kantarjian; Francis Giles; Maher Albitar
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes.
Cancer 2004;100(9):1884-91.
2004: Maher Albitar; Weidong Zhou; Francis Giles
Myelodysplastic syndrome: from morphology to biology.
Current hematology reports 2004;3(3):159-64.
2004: Amit Panwalkar; Srdan Verstovsek; Francis Giles
Nuclear factor-kappaB modulation as a therapeutic approach in hematologic malignancies.
Cancer 2004;100(8):1578-89.
2004: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Francis Giles; Mary Beth Rios; Jianqin Shan; Laurie Letvak; Deborah Thomas; Stefan Faderl; Alessandra Ferrajoli; Jorge Cortes
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia.
Blood 2004;103(8):2873-8.
2004: Anne S Tsao; Andrew Lamb; Deborah Thomas; Francis Giles; Jorge Cortes; Guillermo Garcia-Manero; Yang Huh; Ying Yang; Yu Shen; Maher Albitar; Elihu Estey
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome.
Leukemia research 2004;28(4):373-8.
2004: Francis Giles; Jorge E Cortes; Hagop M Kantarjian; Susan M O'Brien; Elihu Estey; Miloslav Beran
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia.
Leukemia research 2004;28(4):353-7.
2004: Maha M T El-Zimaity; Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Deborah Thomas; Alessandra Ferrajoli; Kimberly Hayes; B Nebiyou Bekele; Xian Zhou; Mary B Rios; Armand B. Glassman; Jorge E Cortes
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome.
British journal of haematology 2004;125(2):187-95.
2004: Francis Giles; Andrew Lamb; Jorge Cortes
Novel therapies for patients with chronic myeloid leukemia.
Expert review of anticancer therapy 2004;4(2):271-82.
2004: Razelle Kurzrock; Maher Albitar; Jorge E Cortes; Elihu H Estey; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Francis Giles; Mary Ellen Ryback; Alain Thibault; P De Porre; Hagop M Kantarjian
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(7):1287-92.
2004: Francis Giles; Martin S Tallman; Guillermo Garcia-Manero; Jorge E Cortes; Deborah A Thomas; William G Wierda; Srdan Verstovsek; Marta Hamilton; Emma Barrett; Maher Albitar; Hagop M Kantarjian
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Cancer 2004;100(7):1449-58.
2004: Anna Rogers; Youngson Joe; Taghi Manshouri; Amanda Dey; Iman Jilani; Francis Giles; Elihu Estey; Emil J Freireich; Michael Keating; Andrew Lamb; Maher Albitar
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia.
Blood 2004;103(7):2799-801.
2004: Nada Orsolic; Francis Giles; Henriette Gourdeau; Mirna Golemovic; Miloslav Beran; Jorge Cortes; Emil J Freireich; Andrew Lamb; Srdan Verstovsek
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation.
British journal of haematology 2004;124(6):727-38.
2004: Jean-Pierre J Issa; Guillermo Garcia-Manero; Francis Giles; Rajan Mannari; Deborah Thomas; Stefan Faderl; Emel Bayar; John Lyons; Craig S Rosenfeld; Jorge Cortes; Hagop M Kantarjian
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies.
Blood 2004;103(5):1635-40.
2004: Amit Panwalkar; Srdan Verstovsek; Francis Giles
Mammalian target of rapamycin inhibition as therapy for hematologic malignancies.
Cancer 2004;100(4):657-66.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Jorge Romaguera; Madeleine Duvic; Razelle Kurzrock
Activity of interferon-alpha and isotretinoin in patients with advanced, refractory lymphoid malignancies.
Cancer 2004;100(3):574-80.
2004: Gloria N Mattiuzzi; Andrew Lamb; Susan O'Brien; Dimitrios P Kontoyiannis; Francis Giles; Xian Zhou; JoAnn Lim; B Nebiyou Bekele; Stefan Faderl; Jorge Cortes; Sherry Pierce; Gerhard J Leitz; Issam Raad; Elihu Estey
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.
Cancer 2004;100(3):568-73.
2004: Farhad Ravandi; Andrew Lamb; Francis Giles; Jorge Cortes
New agents in acute myeloid leukemia and other myeloid disorders.
Cancer 2004;100(3):441-54.
2004: Apostolia-Maria Tsimberidou; Francis Giles; Madeleine Duvic; Luis Fayad; Razelle Kurzrock
Phase II study of pentostatin in advanced T-cell lymphoid malignancies: update of an M.D. Anderson Cancer Center series.
Cancer 2004;100(2):342-9.
2004: Maurizio Zangari; Elias Anaissie; Alison T Stopeck; Alyssa Morimoto; Nguyen Tan; Jeffrey E Lancet; Maureen Cooper; Alison L Hannah; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb; Julie M Cherrington; Maher Albitar; Francis Giles
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):88-95.
2004: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Jianqin Shan; Mary Beth Rios; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; William G Wierda; Steven M Kornblau; Alessandra Ferrajoli; Michael Keating; Moshe Talpaz
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):68-75.
2004: Thomas B Sneed; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rios; B Nebiyou Bekele; Xian Zhou; Debra Resta; William G Wierda; Stefan Faderl; Francis Giles; Jorge E Cortes
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase.
Cancer 2004;100(1):116-21.
2003: Susan M O'Brien; Hagop M Kantarjian; Deborah A Thomas; Jorge Cortes; Francis Giles; William G Wierda; Charles Koller; Alessandra Ferrajoli; Mary L Browning; Susan Lerner; Maher Albitar; Michael J Keating
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia.
Cancer 2003;98(12):2657-63.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Michael Keating; Moshe Talpaz
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data.
Cancer 2003;98(12):2636-42.
2003: Bryan T. J. Hennessy; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis Giles
DNA methylation in haematological malignancies: the role of decitabine.
Expert opinion on investigational drugs 2003;12(12):1985-93.
2003: Francis Giles; Julie M Vose; Kim-Anh Do; Marcella M Johnson; Taghi Manshouri; Gregory Bociek; Philip J Bierman; Susan M O'Brien; Michael J Keating; Hagop M Kantarjian; James O Armitage; Maher Albitar
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease.
British journal of haematology 2003;123(5):850-7.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge E Cortes; Guillermo Garcia-Manero; Stefan Faderl; Srdan Verstovsek; Deborah A Thomas; Alessandra Ferrajoli; Michael J Keating; Susan O'Brien; Hagop M Kantarjian; Francis Giles
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2003;52(6):449-52.
2003: Francis Giles; Eric J Feldman; Gail J Roboz; Richard A Larson; Steven W Mamus; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; Moshe Talpaz; Miloslav Beran; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase.
Leukemia research 2003;27(12):1091-6.
2003: Francis Giles; Paula M Fracasso; Hagop M Kantarjian; Jorge E Cortes; Randy A Brown; Srdan Verstovsek; Yesid Alvarado; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Lisa P Wright; Tom Samson; Ann Cahill; Paula Lambert; William Plunkett; Mario Sznol; John F DiPersio; Varsha Gandhi
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Leukemia research 2003;27(12):1077-83.
2003: Deborah A Thomas; Susan O'Brien; Carlos E Bueso-Ramos; Stefan Faderl; Michael J Keating; Francis Giles; Jorge Cortes; Hagop M Kantarjian
Rituximab in relapsed or refractory hairy cell leukemia.
Blood 2003;102(12):3906-11.
2003: Francis Giles; Elihu Estey; Susan O'Brien
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia.
Cancer 2003;98(10):2095-104.
2003: Iman Jilani; Susan O'Brien; Taghi Manshuri; Deborah A Thomas; Vilmos A Thomazy; Maha Imam; Sana Naeem; Srdan Verstovsek; Andrew Lamb; Francis Giles; Michael Keating; Maher Albitar
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia.
Blood 2003;102(10):3514-20.
2003: Deborah A Thomas; Elihu Estey; Francis Giles; Stefan Faderl; Jorge Cortes; Michael Keating; Susan O'Brien; Maher Albitar; Andrew Lamb
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia.
British journal of haematology 2003;123(3):436-41.
2003: Yana Zhang; Zhiqing Wang; Haichao Liu; Francis Giles; Seah H Lim
Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(6):461-7.
2003: Jorge Medina; Andrew Lamb; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Francis Giles; Mary Beth Rios; Kimberly Hayes; Jorge Cortes
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Cancer 2003;98(9):1905-11.
2003: Salim Yazji; Francis Giles; Apostolia-Maria Tsimberidou; Elihu H Estey; Hagop M Kantarjian; S A O'Brien; Razelle Kurzrock
Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes.
Leukemia 2003;17(11):2101-6.
2003: Blake Tomkinson; Raymond A Bendele; Francis Giles; Eric Brown; Atherton Gray; Karen Hart; Jeremy D LeRay; Denny Meyer; Michelle Pelanne; David L Emerson
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
Leukemia research 2003;27(11):1039-50.
2003: Jorge Cortes; Francis Giles
New agents in chronic myelogenous leukemia.
Journal of the National Comprehensive Cancer Network : JNCCN 2003;1(4):501-12.
2003: Apostolia-Maria Tsimberidou; Francis Giles; Hagop M Kantarjian; Michael J Keating; Susan M O'Brien
Anti-B4 blocked ricin post chemotherapy in patients with chronic lymphocytic leukemia--long-term follow-up of a monoclonal antibody-based approach to residual disease.
Leukemia & lymphoma 2003;44(10):1719-25.
2003: Mihaela Onciu; Elihu Estey; Francis Giles
Circulating blasts following chemotherapy in pediatric patients: implications for complete remission definition in acute leukemia.
Hematology (Amsterdam, Netherlands) 2003;8(5):295-301.
2003: Andrew Lamb; Susan O'Brien; Jorges Cortes; Jianqin Shan; Francis Giles; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Mary Beth Rios; Moshe Talpaz
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase.
Cancer 2003;98(7):1430-7.
2003: Jeong N Lee; Francis Giles; Yang O Huh; Taghi Manshouri; Susan O'Brien; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia.
European journal of haematology 2003;71(4):235-42.
2003: Apostolia-Maria Tsimberidou; Jorge Cortes; Deborah Thomas; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Maher Albitar; Andrew Lamb; Elihu Estey; Francis Giles
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
Leukemia research 2003;27(10):893-7.
2003: Efrosyni Apostolidou; Jorge Cortes; Apostolia-Maria Tsimberidou; Elihu Estey; Andrew Lamb; Francis Giles
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia.
Leukemia research 2003;27(10):887-91.
2003: Andrew Lamb; Varsha Gandhi; Jorge Cortes; Srdan Verstovsek; Min Du; Guillermo Garcia-Manero; Francis Giles; Stefan Faderl; Susan O'Brien; Sima Jeha; Jan Davis; Zeev Shaked; Adam Craig; Michael Keating; William Plunkett; Emil J Freireich
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Blood 2003;102(7):2379-86.
2003: Miloslav Beran; Susan O'Brien; Deborah A Thomas; Hai T Tran; Jorge E Cortes-Franco; Francis Giles; Elihu Estey; Hagop M Kantarjian
Phase I study of oral topotecan in hematological malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(11):4084-91.
2003: Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Jianquin Shan; Stefan Faderl; Guillermo Garcia-Manero; Alessandra Ferrajoli; William G Wierda; Andrew Lamb
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;98(6):1105-13.
2003: Susan O'Brien; Francis Giles; Moshe Talpaz; Jorge Cortes; Mary Beth Rios; Jianqin Shan; Deborah Thomas; Michael Andreeff; Steven M Kornblau; Stefan Faderl; Guillermo Garcia-Manero; Kevin White; Susie Mallard; Emil J Freireich; Hagop M Kantarjian
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase.
Cancer 2003;98(5):888-93.
2003: Maha Ahmed; Francis Giles; Youngson Joe; Donna M Weber; Iman Jilani; Taghi Manshouri; Sergio Giralt; Marcos De Lima; Michael Keating; Maher Albitar
Use of plasma DNA in detection of loss of heterozygosity in patients with multiple myeloma.
European journal of haematology 2003;71(3):174-8.
2003: Francis Giles; Jorge E Cortes; Terri A Halliburton; Susie J Mallard; Elihu H Estey; Tracey A Waddelow; JoAnn T Lim
Intravenous corticosteroids to reduce gemtuzumab ozogamicin infusion reactions.
The Annals of pharmacotherapy 2003;37(9):1182-5.
2003: Apostolia-Maria Tsimberidou; Dawn E Colburn; Mary Alma Welch; Jorge E Cortes; Srdan Verstovsek; Susan M O'Brien; Maher Albitar; Hagop M Kantarjian; Francis Giles
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
Cancer chemotherapy and pharmacology 2003;52(3):229-34.
2003: Francis Giles; Gary Guangping Shi; Jorge E Cortes; Deborah Thomas; Anna R Keating; Hagop M Kantarjian; Michael J Keating; Susan M O'Brien
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia.
Cancer chemotherapy and pharmacology 2003;52(3):223-8.
2003: Hesham M Amin; Iman Jilani; Elihu H Estey; Michael J Keating; Amanda L Dey; Taghi Manshouri; Hagop M Kantarjian; Zeev Estrov; Jorge E Cortes; Deborah A Thomas; Francis Giles; Maher Albitar
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome.
Blood 2003;102(5):1866-8.
2003: Alessandra Ferrajoli; Susan M O'Brien; Jorge E Cortes; Francis Giles; Deborah A Thomas; Stefan Faderl; Razelle Kurzrock; Susan Lerner; Dimitrios P Kontoyiannis; Michael J Keating
Phase II study of alemtuzumab in chronic lymphoproliferative disorders.
Cancer 2003;98(4):773-8.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Jean-Pierre J Issa; Guillermo Garcia-Manero; Mary Beth Rios; Jianqin Shan; Michael Andreeff; Michael Keating; Moshe Talpaz
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Cancer 2003;98(3):522-8.
2003: Francis Giles; Alison T Stopeck; Lewis R Silverman; Jeffrey E Lancet; Maureen A Cooper; Alison L Hannah; Julie M Cherrington; Anne-Marie O'Farrell; Helene A Yuen; Sharianne G Louie; Weiru Hong; Jorge E Cortes; Srdan Verstovsek; Maher Albitar; Susan M O'Brien; Hagop M Kantarjian; Judith E Karp
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes.
Blood 2003;102(3):795-801.
2003: David Cella; Janis G Pulliam; Henry Fuchs; Carole B Miller; David D Hurd; John R Wingard; Stephen T Sonis; Paul J Martin; Francis Giles
Evaluation of pain associated with oral mucositis during the acute period after administration of high-dose chemotherapy.
Cancer 2003;98(2):406-12.
2003: Susan O'Brien; Francis Giles
Monoclonal antibodies in the treatment of lymphoid leukemia.
Drugs of today (Barcelona, Spain : 1998) 2003;39(7):541-50.
2003: Francis Giles; Carole B Miller; David D Hurd; John R Wingard; Thomas R Fleming; Stephen T Sonis; Williamson Z Bradford; Janis G Pulliam; Elias J Anaissie; Roy A Beveridge; Mark M Brunvand; Paul J Martin
A phase III, randomized, double-blind, placebo-controlled, multinational trial of iseganan for the prevention of oral mucositis in patients receiving stomatotoxic chemotherapy (PROMPT-CT trial).
Leukemia & lymphoma 2003;44(7):1165-72.
2003: Marina Konopleva; Su-Chun Cheng; Jorge E Cortes; Kimberly J Hayes; Sherry A Pierce; Michael Andreeff; Francis Giles; Susan O'Brien; Hagop M Kantarjian; Elihu H Estey
Independent prognostic significance of day 21 cytogenetic findings in newly-diagnosed acute myeloid leukemia or refractory anemia with excess blasts.
Haematologica 2003;88(7):733-6.
2003: Andrew Lamb; Susan O'Brien; Jorge Cortes; Francis Giles; Deborah Thomas; Steven M Kornblau; Jianquin Shan; Mary Beth Rios; Michael Keating; Emil J Freireich; Moshe Talpaz
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications.
Cancer 2003;98(1):81-5.
2003: Srdan Verstovsek; Scott Lunin; Andrew Lamb; Taghi Manshouri; Stefan Faderl; Jorge Cortes; Francis Giles; Maher Albitar
Clinical relevance of VEGF receptors 1 and 2 in patients with chronic myelogenous leukemia.
Leukemia research 2003;27(7):661-9.
2003: Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Guillermo Garcia-Manero; Mary Beth Rios; Stefan Faderl; Srdan Verstovsek; Alessandra Ferrajoli; Emil J Freireich; Moshe Talpaz; Andrew Lamb
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha.
Blood 2003;102(1):83-6.
2003: Guillermo Garcia-Manero; Moshe Talpaz; Francis Giles; Jorge Cortes; Stefan Faderl; Susan O'Brien; Deborah Thomas; Srdan Verstovsek; Mary Beth Rios; Jianquin Shan; Alessandra Ferrajoli; William G Wierda; Hagop M Kantarjian
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside.
Cancer 2003;97(12):3010-6.
2003: Jorge Cortes; Francis Giles; Susan O'Brien; Deborah Thomas; Maher Albitar; Mary Beth Rios; Moshe Talpaz; Guillermo Garcia-Manero; Stefan Faderl; Laurie Letvak; August Salvado; Andrew Lamb
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders.
Cancer 2003;97(11):2760-6.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Elihu Estey; Jorge E Cortes; Srdan Verstovsek; Stefan Faderl; D A Thomas; Guillermo Garcia-Manero; Alessandra Ferrajoli; John T Manning; Michael J Keating; Maher Albitar; Susan O'Brien; Francis Giles
Outcome in patients with nonleukemic granulocytic sarcoma treated with chemotherapy with or without radiotherapy.
Leukemia 2003;17(6):1100-3.
2003: Elihu Estey; Francis Giles; Jorge Cortes; Miloslav Beran; Srdan Verstovsek; Guillermo Garcia-Manero; Stefan Faderl; Andrew Lamb
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
Leukemia research 2003;27(6):475-9.
2003: Jorge E Cortes; Moshe Talpaz; Francis Giles; Susan O'Brien; Mary Beth Rios; Jianqin Shan; Guillermo Garcia-Manero; Stefan Faderl; Deborah A Thomas; William G Wierda; Alessandra Ferrajoli; Sima Jeha; Hagop M Kantarjian
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy.
Blood 2003;101(10):3794-800.
2003: Francis Giles; B Nebiyou Bekele; Susan O'Brien; Jorge E Cortes; Srdan Verstovsek; Maria Balerdi; Marwan Yared; Xian Zhou; Hagop M Kantarjian; Michael J Keating; Peter F Thall; Maher Albitar
A prognostic model for survival in chronic lymphocytic leukaemia based on p53 expression.
British journal of haematology 2003;121(4):578-85.
2003: Hatice Duzkale; Iman Jilani; Nada Orsolic; Ralph A Zingaro; Mirna Golemovic; Francis Giles; Andrew Lamb; Maher Albitar; Emil J Freireich; Srdan Verstovsek
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines.
Cancer chemotherapy and pharmacology 2003;51(5):427-32.
2003: Francis Giles; Hagop M Kantarjian; Jorge E Cortes; Guillermo Garcia-Manero; Srdan Verstovsek; Stefan Faderl; Deborah A Thomas; Alessandra Ferrajoli; Susan O'Brien; J Kyle Wathen; Lian-Chun Xiao; Donald A Berry; Elihu H Estey
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(9):1722-7.
2003: Andrew Lamb; Moshe Talpaz; Susan O'Brien; Francis Giles; Mary Beth Rios; Kevin White; Guillermo Garcia-Manero; Alessandra Ferrajoli; Srdan Verstovsek; William G Wierda; Steven M Kornblau; Jorge Cortes
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
Cancer 2003;97(9):2225-8.
2003: Srdan Verstovsek; Taghi Manshouri; Franklin O Smith; Francis Giles; Jorge Cortes; Elihu Estey; Andrew Lamb; Michael Keating; Sima Jeha; Maher Albitar
Telomerase activity is prognostic in pediatric patients with acute myeloid leukemia: comparison with adult acute myeloid leukemia.
Cancer 2003;97(9):2212-7.
2003: Apostolia-Maria Tsimberidou; Tracey A Waddelow; Hagop M Kantarjian; Maher Albitar; Francis Giles
Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Leukemia research 2003;27(5):375-80.
2003: Stefan Faderl; Deborah A Thomas; Susan O'Brien; Guillermo Garcia-Manero; Hagop M Kantarjian; Francis Giles; Charles Koller; Alessandra Ferrajoli; Srdan Verstovsek; Barbara Pro; Michael Andreeff; Miloslav Beran; Jorge Cortes; William G Wierda; Ngoc Tran; Michael J Keating
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies.
Blood 2003;101(9):3413-5.
2003: Francis Giles; Maureen A Cooper; Lewis Silverman; Judith E Karp; Jeffrey E Lancet; Maurizio Zangari; Paul J Shami; Khuda Dad Khan; Alison L Hannah; Julie M Cherrington; Deborah A Thomas; Guillermo Garcia-Manero; Maher Albitar; Hagop M Kantarjian; Alison T Stopeck
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Cancer 2003;97(8):1920-8.
2003: Sherif Ibrahim; Iman Jilani; Susan O'Brien; Anna Rogers; Taghi Manshouri; Francis Giles; Stefan Faderl; Deborah Thomas; Andrew Lamb; Michael Keating; Maher Albitar
Clinical relevance of the expression of the CD31 ligand for CD38 in patients with B-cell chronic lymphocytic leukemia.
Cancer 2003;97(8):1914-9.
2003: Lance H Leopold; Mark S Berger; Su-Chun Cheng; Jorge E Cortes-Franco; Francis Giles; Elihu H Estey
Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Clinical advances in hematology & oncology : H&O 2003;1(4):220-5.
2003: Apostolia-Maria Tsimberidou; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Srdan Verstovsek; Alessandra Ferrajoli; William G Wierda; Yesid Alvarado; Susan M O'Brien; Maher Albitar; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia.
Cancer 2003;97(7):1711-20.
2003: Efrosyni Apostolidou; Elihu Estey; Jorge Cortes; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Apostolia-Maria Tsimberidou; Andrew Lamb; Francis Giles
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia.
Leukemia research 2003;27(4):301-4.
2003: Taghi Manshouri; Kim-Anh Do; Xuemei Wang; Francis Giles; Susan M O'Brien; Helene Saffer; Deborah Thomas; Iman Jilani; Hagop M Kantarjian; Michael J Keating; Maher Albitar
Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance.
Blood 2003;101(7):2507-13.
2003: Hagop M Kantarjian; Varsha Gandhi; Peter Kozuch; Stefan Faderl; Francis Giles; Jorge Cortes; Susan O'Brien; Nuhad Ibrahim; Fadlo R Khuri; Min Du; Mary Beth Rios; Sima Jeha; Peter McLaughlin; William Plunkett; Michael Keating
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1167-73.
2003: Francis Giles; Stefan Faderl; Deborah A Thomas; Jorge E Cortes; Guillermo Garcia-Manero; Dan Douer; Alexandra M Levine; Charles Koller; Sima Jeha; Susan M O'Brien; Elihu H Estey; Hagop M Kantarjian
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(6):1050-6.
2003: Apostolia-Maria Tsimberidou; Elihu Estey; Jorge Cortes; Deborah Thomas; Stefan Faderl; Srdan Verstovsek; Guillermo Garcia-Manero; Michael Keating; Maher Albitar; Susan O'Brien; Andrew Lamb; Francis Giles
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes.
Cancer 2003;97(6):1481-7.
2003: A-M Tsimberidou; J Medina; M Earl; M Sierra; J E Shriki; C Bueso-Ramos; Sergio Giralt; M Beran; Francis Giles; G Garcia-Manero
Metastatic gastric adenocarcinoma following allogeneic stem cell transplantation in a patient with acute myelogenous leukemia.
Bone marrow transplantation 2003;31(5):413-4.
2003: Gloria N Mattiuzzi; Jorge E Cortes; Moshe Talpaz; James M Reuben; Mary Beth Rios; Jianjin Shan; Dimitrios P Kontoyiannis; Francis Giles; Issam Raad; Srdan Verstovsek; Alessandra Ferrajoli; Hagop M Kantarjian
Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(3):976-80.
2003: Srdan Verstovsek; Andrew Lamb; Taghi Manshouri; Jorge Cortes; Stefan Faderl; Francis Giles; Michael Keating; Maher Albitar
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia.
Cancer 2003;97(5):1248-52.
2003: Jorge Cortes; Andrew Lamb; Maher Albitar; Deborah Thomas; Stefan Faderl; Charles Koller; Guillermo Garcia-Manero; Francis Giles; Michael Andreeff; Susan O'Brien; Michael Keating; Elihu Estey
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.
Cancer 2003;97(5):1234-41.
2003: Jorge Cortes; Maher Albitar; Deborah Thomas; Francis Giles; Razelle Kurzrock; Alain Thibault; Wayne Rackoff; Charles Koller; Susan O'Brien; Guillermo Garcia-Manero; Moshe Talpaz; Andrew Lamb
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Blood 2003;101(5):1692-7.
2003: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Jianqin Shan; Francis Giles; Mary Beth Rios; Stefan Faderl; William G Wierda; Alessandra Ferrajoli; Srdan Verstovsek; Michael J Keating; Emil J Freireich; Moshe Talpaz
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis.
Cancer 2003;97(4):1033-41.
2003: Dawn E Colburn; Deborah A Thomas; Francis Giles
Phase II study of single agent paclitaxel in adult patients with relapsed acute lymphocytic leukemia.
Investigational new drugs 2003;21(1):109-11.
2003: Alvaro Aguayo; Francis Giles; Maher Albitar
Vascularity, angiogenesis and angiogenic factors in leukemias and myelodysplastic syndromes.
Leukemia & lymphoma 2003;44(2):213-22.
2003: William G Wierda; Marcella M Johnson; Kim-Anh Do; Taghi Manshouri; Amanda Dey; Susan O'Brien; Francis Giles; Andrew Lamb; Deborah Thomas; Stefan Faderl; Susan Lerner; Michael Keating; Maher Albitar
Plasma interleukin 8 level predicts for survival in chronic lymphocytic leukaemia.
British journal of haematology 2003;120(3):452-6.
2003: Gloria N Mattiuzzi; Elihu Estey; Issam Raad; Francis Giles; Jorge Cortes; Yu Shen; Dimitrios P Kontoyiannis; Charles Koller; Mark F Munsell; Miloslav Beran; Andrew Lamb
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome.
Cancer 2003;97(2):450-6.
2003: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Jianqin Shan; Mary Beth Rios; Jorge Cortes
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia.
Blood 2003;101(2):473-5.
2003: Hagop M Kantarjian; Moshe Talpaz; Jorge Cortes; Susan O'Brien; Stefan Faderl; Deborah Thomas; Francis Giles; Mary Beth Rios; Jianqin Shan; Ralph B Arlinghaus
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):160-6.
2003: Iman Jilani; Elihu Estey; T Manshuri; M Caligiuri; Michael Keating; Francis Giles; Deborah Thomas; Andrew Lamb; Maher Albitar
Better detection of FLT3 internal tandem duplication using peripheral blood plasma DNA.
Leukemia 2003;17(1):114-9.
2003: Yesid Alvarado; Apostolia-Maria Tsimberidou; Andrew Lamb; Jorge Cortes; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Elihu Estey; Francis Giles
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.
Cancer chemotherapy and pharmacology 2003;51(1):87-90.
2003: Yesid Alvarado; Jorge Cortes; Srdan Verstovsek; Deborah Thomas; Stefan Faderl; Zeev Estrov; Andrew Lamb; Francis Giles
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia.
Cancer chemotherapy and pharmacology 2003;51(1):81-6.
2003: Hagop M Kantarjian; Jorge E Cortes; Susan O'Brien; Francis Giles; Guillermo Garcia-Manero; Stefan Faderl; Deborah Thomas; Sima Jeha; Mary Beth Rios; Laurie Letvak; Kathy Bochinski; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses.
Blood 2003;101(1):97-100.
2002: Francis Giles
Gemtuzumab ozogamicin: promise and challenge in patients with acute myeloid leukemia.
Expert review of anticancer therapy 2002;2(6):630-40.
2002: Apostolia-Maria Tsimberidou; Francis Giles
Essential thrombocythemia (ET): moving from palliation to cure.
Hematology (Amsterdam, Netherlands) 2002;7(6):315-23.
2002: Jorge Cortes; Apostolia-Maria Tsimberidou; Ricardo Alvarez; Deborah Thomas; Miloslav Beran; Andrew Lamb; Elihu Estey; Francis Giles
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
Cancer chemotherapy and pharmacology 2002;50(6):497-500.
2002: Alvaro Aguayo; Hagop M Kantarjian; Elihu H Estey; Francis Giles; Srdan Verstovsek; Taghi Manshouri; Christy Gidel; Susan O'Brien; Michael J Keating; Maher Albitar
Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes.
Cancer 2002;95(9):1923-30.
2002: Yang O Huh; Iman Jilani; Elihu Estey; Francis Giles; Andrew Lamb; Emil J Freireich; Maher Albitar
More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia.
Leukemia 2002;16(11):2249-52.
2002: Yesid Alvarado; Lisa A Bellm; Francis Giles
Oral mucositis: time for more studies.
Hematology (Amsterdam, Netherlands) 2002;7(5):281-9.
2002: Francis Giles
Leukapheresis in patients with previously untreated acute myeloid leukemia.
Therapeutic apheresis : official journal of the International Society for Apheresis and the Japanese Society for Apheresis 2002;6(5):399-400.
2002: Iman Jilani; Elihu Estey; Yang Huh; Youngson Joe; Taghi Manshouri; Marwan Yared; Francis Giles; Andrew Lamb; Jorge Cortes; Deborah Thomas; Michael Keating; Emil J Freireich; Maher Albitar
Differences in CD33 intensity between various myeloid neoplasms.
American journal of clinical pathology 2002;118(4):560-6.
2002: Francis Giles; Guillermo Garcia-Manero; Jorge Cortes; Deborah Thomas; Andrew Lamb; Elihu Estey
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy.
Haematologica 2002;87(10):1114-6.
2002: Francis Giles; Hagop M Kantarjian; B Nebiyou Bekele; Jorge E Cortes; Stefan Faderl; Deborah A Thomas; Taghi Manshouri; Anna Rogers; Michael J Keating; Moshe Talpaz; Susan O'Brien; Maher Albitar
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival.
British journal of haematology 2002;119(1):38-45.
2002: Apostolia-Maria Tsimberidou; Deborah Thomas; Susan O'Brien; Michael Andreeff; Razelle Kurzrock; Michael Keating; Maher Albitar; Andrew Lamb; Francis Giles
Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Cancer chemotherapy and pharmacology 2002;50(3):237-42.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Sergio Giralt; Mary Beth Rios; Jianqin Shan; Francis Giles; Deborah A Thomas; Stefan Faderl; Marcos De Lima; Guillermo Garcia-Manero; Richard Champlin; Ralph B Arlinghaus; Moshe Talpaz
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Blood 2002;100(5):1590-5.
2002: Francis Giles
New drugs in acute myeloid leukemia.
Current oncology reports 2002;4(5):369-74.
2002: Alessandra Ferrajoli; Michael J Keating; Taghi Manshouri; Francis Giles; Amanda Dey; Zeev Estrov; Charles Koller; Razelle Kurzrock; Deborah A Thomas; Stefan Faderl; Susan Lerner; Susan O'Brien; Maher Albitar
The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia.
Blood 2002;100(4):1215-9.
2002: Apostolia-Maria Tsimberidou; Yesid Alvarado; Francis Giles
Evolving role of ribonucleoside reductase inhibitors in hematologic malignancies.
Expert review of anticancer therapy 2002;2(4):437-48.
2002: Guillermo Garcia-Manero; Stefan Faderl; Francis Giles; Deborah Thomas; Jorge Cortes; Susan O'Brien; Jan Davis; Hagop M Kantarjian; Elihu Estey
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.
Haematologica 2002;87(8):804-7.
2002: Francis Giles; Rebecca Redman; Salim Yazji; Lisa A Bellm
Iseganan HCl: a novel antimicrobial agent.
Expert opinion on investigational drugs 2002;11(8):1161-70.
2002: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Terry L Smith; Francis Giles; Stefan Faderl; Deborah A Thomas; Guillermo Garcia-Manero; Jean-Pierre J Issa; Michael Andreeff; Steven M Kornblau; Charles Koller; Miloslav Beran; Michael Keating; Mary Beth Rios; Jianqin Shan; Debra Resta; Renaud Capdeville; Kimberly Hayes; Maher Albitar; Emil J Freireich; Jorge E Cortes
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2177-87.
2002: Hagop M Kantarjian; Susan O'Brien; Jorge E Cortes; Terry L Smith; Mary Beth Rios; Jianqin Shan; Ying Yang; Francis Giles; Deborah A Thomas; Stefan Faderl; Guillermo Garcia-Manero; Sima Jeha; William G Wierda; Jean-Pierre J Issa; Steven M Kornblau; Michael Keating; Debra Resta; Renaud Capdeville; Moshe Talpaz
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2167-76.
2002: Francis Giles; Jorge E Cortes; Deborah A Thomas; Guillermo Garcia-Manero; Stefan Faderl; Sima Jeha; Robert L De Jager; Hagop M Kantarjian
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(7):2134-41.
2002: Srdan Verstovsek; Elihu Estey; Taghi Manshouri; Francis Giles; Jorge Cortes; Miloslav Beran; Anna Rogers; Michael Keating; Andrew Lamb; Maher Albitar
Clinical relevance of vascular endothelial growth factor receptors 1 and 2 in acute myeloid leukaemia and myelodysplastic syndrome.
British journal of haematology 2002;118(1):151-6.
2002: Farhad Ravandi; Jorge Cortes; Zeev Estrov; Deborah Thomas; Francis Giles; Yang O Huh; Sherry Pierce; Susan O'Brien; Stefan Faderl; Hagop M Kantarjian
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia.
Leukemia research 2002;26(7):643-9.
2002: Elihu H Estey; Peter F Thall; Francis Giles; Xue-Mei Wang; Jorge E Cortes; Miloslav Beran; Sherry A Pierce; Deborah A Thomas; Hagop M Kantarjian
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinoside.
Blood 2002;99(12):4343-9.
2002: Dawn E Colburn; Mary Alma Welch; Francis Giles
Skin infiltration with chronic lymphocytic leukemia is consistent with a good prognosis.
Hematology (Amsterdam, Netherlands) 2002;7(3):187-8.
2002: Yesid Alvarado; Hagop M Kantarjian; Jorge E Cortes; Effrosyni Apostolidou; Carol Bivins; Francis Giles
Troxacitabine activity in extramedullary myeloid leukemia.
Hematology (Amsterdam, Netherlands) 2002;7(3):179-85.
2002: Apostolia-Maria Tsimberidou; Francis Giles
TNF-alpha targeted therapeutic approaches in patients with hematologic malignancies.
Expert review of anticancer therapy 2002;2(3):277-86.
2002: Francis Giles
Troxacitabine-based therapy of refractory leukemia.
Expert review of anticancer therapy 2002;2(3):261-6.
2002: Elihu H Estey; Francis Giles; Miloslav Beran; Susan O'Brien; Sherry A Pierce; Stefan Faderl; Jorge E Cortes; Hagop M Kantarjian
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia.
Blood 2002;99(11):4222-4.
2002: Ann Mohrbacher; Stephanie A Gregory; Don A Gabriel; Jason M Rusk; Francis Giles
Liposomal daunorubicin (DaunoXome) plus dexamethasone for patients with multiple myeloma. A phase II International Oncology Study Group study.
Cancer 2002;94(10):2645-52.
2002: Hagop M Kantarjian; Jorge Cortes; Susan O'Brien; Francis Giles; Maher Albitar; Mary Beth Rios; Jianqin Shan; Stefan Faderl; Guillermo Garcia-Manero; Deborah A Thomas; Debra Resta; Moshe Talpaz
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase.
Blood 2002;99(10):3547-53.
2002: Francis Giles
The emerging role of angiogenesis inhibitors in hematologic malignancies.
Oncology (Williston Park, N.Y.) 2002;16(5 Suppl 4):23-9.
2002: Apostolia-Maria Tsimberidou; Susan M O'Brien; Jorge E Cortes; Stefan Faderl; Michael Andreeff; Hagop M Kantarjian; Michael J Keating; Francis Giles
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders.
Leukemia & lymphoma 2002;43(4):767-72.
2002: Susan O'Brien; Moshe Talpaz; Jorge Cortes; Jianqin Shan; Francis Giles; Stefan Faderl; Deborah Thomas; Guillermo Garcia-Manero; Susie Mallard; Mary Beth; Charles Koller; Steven M Kornblau; Michael Andreeff; Anthony J Murgo; Michael Keating; Hagop M Kantarjian
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia.
Cancer 2002;94(7):2024-32.
2002: Srdan Verstovsek; Andrew Lamb; Taghi Manshouri; Jorge Cortes; Francis Giles; Anna Rogers; Maher Albitar
Prognostic significance of cellular vascular endothelial growth factor expression in chronic phase chronic myeloid leukemia.
Blood 2002;99(6):2265-7.
2002: Yuk Fung Hui; Francis Giles; Jorge E Cortes
Chemotherapy-induced palmar-plantar erythrodysesthesia syndrome--recall following different chemotherapy agents.
Investigational new drugs 2002;20(1):49-53.
2002: Usha R Surapaneni; Jorge E Cortes; Deborah Thomas; Susan O'Brien; Francis Giles; Charles Koller; Stefan Faderl; Andrew Lamb
Central nervous system relapse in adults with acute lymphoblastic leukemia.
Cancer 2002;94(3):773-9.
2002: Francis Giles; Guillermo Garcia-Manero; Jorge E Cortes; Sharyn D Baker; Carole B Miller; Susan M O'Brien; Deborah A Thomas; Michael Andreeff; Carol Bivins; Jacques Jolivet; Hagop M Kantarjian
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):656-64.
2002: Francis Giles; Armand Keating; Anthony H Goldstone; Irit Avivi; Cheryl L Willman; Hagop M Kantarjian
Acute myeloid leukemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2002;():73-110.
2002: Francis Giles; Guillermo Garcia-Manero; Susan O'Brien; Eihu Estey; Andrew Lamb
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome.
Acta haematologica 2002;108(3):164-7.
2002: Francis Giles
Novel agents for the therapy of acute leukemia.
Current opinion in oncology 2002;14(1):3-9.
2001: Elihu H Estey; Peter F Thall; Jorge E Cortes; Francis Giles; Susan O'Brien; Sherry A Pierce; Xuemei Wang; Hagop M Kantarjian; Miloslav Beran
Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts.
Blood 2001;98(13):3575-83.
2001: Hagop M Kantarjian; Jianqin Shan; Terry Smith; Moshe Talpaz; Peter Kozuch; Mary Beth Rios; Jorge Cortes; Francis Giles; Susan O'Brien
Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase.
Cancer 2001;92(10):2501-7.
2001: Jorge Cortes; Susan O'Brien; J Loscertales; Andrew Lamb; Francis Giles; Deborah Thomas; Charles Koller; Michael Keating
Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.
Cancer 2001;92(8):2016-22.
2001: Miloslav Beran; Yu Shen; Andrew Lamb; Susan O'Brien; Charles Koller; Francis Giles; Jorge Cortes; Deborah A Thomas; Stefan Faderl; Simona Despa; Elihu H Estey
High-dose chemotherapy in high-risk myelodysplastic syndrome: covariate-adjusted comparison of five regimens.
Cancer 2001;92(8):1999-2015.
2001: Moshe Talpaz; Susan O'Brien; E Rose; S Gupta; Jianqin Shan; Jorge Cortes; Francis Giles; Stefan Faderl; Hagop M Kantarjian
Phase 1 study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia.
Blood 2001;98(6):1708-13.
2001: Srdan Verstovsek; Andrew Lamb; Elihu Estey; Alvaro Aguayo; Francis Giles; Taghi Manshouri; Charles Koller; Zeev Estrov; Emil J Freireich; Michael Keating; Maher Albitar
Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome.
Leukemia 2001;15(8):1165-70.
2001: Francis Giles; Hagop M Kantarjian; Steven M Kornblau; Deborah A Thomas; Guillermo Garcia-Manero; Tracey A Waddelow; Cynthia L David; Alexandria Phan; Dawn E Colburn; Asif Rashid; Elihu H Estey
Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation.
Cancer 2001;92(2):406-13.
2001: Srdan Verstovsek; Elihu Estey; Taghi Manshouri; Michael Keating; Andrew Lamb; Francis Giles; Maher Albitar
High expression of the receptor tyrosine kinase Tie-1 in acute myeloid leukemia and myelodysplastic syndrome.
Leukemia & lymphoma 2001;42(3):511-6.
2001: Bouthaina S Dabaja; Susan M O'Brien; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Maher Albitar; E S Schlette; Stefan Faderl; Andreas H Sarris; Michael J Keating; Francis Giles
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin (daunoXome), and dexamethasone (hyperCVXD) regimen in Richter's syndrome.
Leukemia & lymphoma 2001;42(3):329-37.
2001: Elihu Estey; Charles Koller; Jorge Cortes; P Reed; Emil J Freireich; Francis Giles; Andrew Lamb
Treatment of newly-diagnosed acute promyelocytic leukemia with liposomal all-trans retinoic acid.
Leukemia & lymphoma 2001;42(3):309-16.
2001: Jorge Cortes; Elihu Estey; Susan O'Brien; Francis Giles; Yu Shen; Charles Koller; Miloslav Beran; Deborah Thomas; Michael Keating; Andrew Lamb
High-dose liposomal daunorubicin and high-dose cytarabine combination in patients with refractory or relapsed acute myelogenous leukemia.
Cancer 2001;92(1):7-14.
2001: Francis Giles; Yu Shen; Hagop M Kantarjian; Martin Korbling; Susan O'Brien; Paolo Anderlini; Michele Donato; Sherry Pierce; Michael J Keating; Emil J Freireich; Elihu Estey
Leukapheresis reduces early mortality in patients with acute myeloid leukemia with high white cell counts but does not improve long- term survival.
Leukemia & lymphoma 2001;42(1-2):67-73.
2001: Farhad Ravandi; Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; Stefan Faderl; Francis Giles; Deborah Thomas; Jorge Cortes; Michael Andreeff; Zeev Estrov; Mary Beth Rios; Maher Albitar
Expression of apoptosis proteins in chronic myelogenous leukemia: associations and significance.
Cancer 2001;91(11):1964-72.
2001: S Verstovsek; T Manshouri; H Kantarjian; Francis Giles; M Keating; E Estey; M Albitar
Highly reproducible detection and semi-quantification of telomerase activity.
BioTechniques 2001;30(5):930-4.
2001: Susan M O'Brien; Andrew Lamb; Deborah A Thomas; Francis Giles; Emil J Freireich; Jorge Cortes; Susan Lerner; Michael J Keating
Rituximab dose-escalation trial in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(8):2165-70.
2001: Francis Giles; H Kantarjian; S O'Brien; M B Rios; J Cortes; M Beran; C Koller; M Keating; Moshe Talpaz
Results of therapy with interferon alpha and cyclic combination chemotherapy in patients with philadelphia chromosome positive chronic myelogenous leukemia in early chronic phase.
Leukemia & lymphoma 2001;41(3-4):309-19.
2001: Ellen Schlette; Carlos E Bueso-Ramos; Francis Giles; Armand B. Glassman; Kimberly Hayes; L Jeffrey Medeiros
Mature B-cell leukemias with more than 55% prolymphocytes. A heterogeneous group that includes an unusual variant of mantle cell lymphoma.
American journal of clinical pathology 2001;115(4):571-81.
2001: J Robert Beck; J Guilhot; Francis Giles; N Aoki; DP Wirt; françois guilhot
Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.
Leukemia & lymphoma 2001;41(1-2):117-24.
2001: Susan M O'Brien; Hagop M Kantarjian; Jorge Cortes; Miloslav Beran; Charles Koller; Francis Giles; Susan Lerner; Michael Keating
Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(5):1414-20.
2001: Beverly D Smolich; Helene A Yuen; K A West; Francis Giles; Maher Albitar; Julie M Cherrington
The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts.
Blood 2001;97(5):1413-21.
2001: DP Wirt; Francis Giles; M M Oken; P Solal-Celigny; J Robert Beck
Cost-Effectiveness of interferon alfa-2b added to chemotherapy for high-tumor-burden follicular non-Hodgkin's lymphoma.
Leukemia & lymphoma 2001;40(5-6):565-79.
2001: Francis Giles; Jorge E Cortes; Sharyn D Baker; Deborah A Thomas; Susan O'Brien; Terry L Smith; Miloslav Beran; Carol Bivins; J Jolivet; Hagop M Kantarjian
Troxacitabine, a novel dioxolane nucleoside analog, has activity in patients with advanced leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(3):762-71.
2001: D A Thomas; Francis Giles; J Cortes; M Albitar; H M Kantarjian
Antiangiogenic therapy in leukemia.
Acta haematologica 2001;106(4):190-207.
2001: Francis Giles
The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies.
The oncologist 2001;6 Suppl 5():32-9.
2001: Francis Giles; Jorge Cortes; Guillermo Garcia-Manero; Steven M Kornblau; Elihu Estey; Monica Kwari; Anthony J Murgo; Andrew Lamb
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Investigational new drugs 2001;19(1):13-20.
2000: Francis Giles; J Shan; S H Advani; H Akan; I Aydogdu; Z Aziz; H A Azim; P P Bapsy; F Buyukkececi; B Chaimongkol; P M Chen; S K Cheong; B Ferhanoglu; R Hamza; H M Khalid; T Intragumtornchai; S W Kim; S Y Kim; H Koc; L Kumar; R Kumar; K I Lei; Arnuparp Lekhakula; A Muthalib; M Patel; V P Poovalingam; W Prayoonwiwat; F Rana; A H Reksodiputro; P Ruff; T G Sagar; A P Schwarer; H S Song; C W Suh; C Suharti; I Supindiman; G Y Tee; T Thamprasit; A H Villalon; N R Wickham; J E Wong; A Yalcin; S Jootar
A prospective randomized study of Chop versus Chop plus alpha-2B interferon in patients with intermediate and high grade non-Hodgkin's lymphoma: the International Oncology Study Group NHL1 Study .
Leukemia & lymphoma 2000;40(1-2):95-103.
2000: Hagop M Kantarjian; Francis Giles; Susan O'Brien; Sergio Giralt; Moshe Talpaz
Therapeutic choices in younger patients with chronic myelogenous leukemia.
Cancer 2000;89(8):1647-58.
2000: Hagop M Kantarjian; Moshe Talpaz; Terry L Smith; Jorge Cortes; Francis Giles; Mary Beth Rios; Susie Mallard; James L Gajewski; Anthony J Murgo; B Cheson; Susan O'Brien
Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(20):3513-21.
2000: C Sriswasdi; S Jootar; Francis Giles
Amifostine and hematologic effects.
Journal of the Medical Association of Thailand = Chotmaihet thangphaet 2000;83(4):374-82.
2000: Francis Giles; J Shan; S Chen; S H Advani; I Supandiman; Z Aziz; A P Caviles; G Y Tee; M R Chasen; Z Fahed; T Y Chaoj; I Aydogdu; A M Lynott
A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the International Oncology Study Group CML1 study.
Leukemia & lymphoma 2000;37(3-4):367-77.
2000: Francis Giles; G C Wong; S J Clark; Sherry Pierce; Hagop M Kantarjian; Michael J Keating
Oral idarubicin in patients with late chronic phase chronic myelogenous leukemia or chronic myelomonocytic leukemia.
Leukemia & lymphoma 2000;37(1-2):87-95.
2000: Francis Giles; N R Wickham; B L Rapoport; G Somlo; S W Lim; J Shan; A M Lynott
Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol.
American journal of hematology 2000;63(3):125-30.
2000: Farhad Ravandi-Kashani; Jorge Cortes; Francis Giles
Myelodysplasia presenting as granulocytic sarcoma of mediastinum causing superior vena cava syndrome.
Leukemia & lymphoma 2000;36(5-6):631-7.
2000: Jorge Cortes; Elihu Estey; Miloslav Beran; Susan O'Brien; Francis Giles; Charles Koller; Michael Keating; Andrew Lamb
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Leukemia & lymphoma 2000;36(5-6):479-84.
2000: N Vey; Francis Giles; Andrew Lamb; Terry L Smith; Miloslav Beran; Sima Jeha
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(2):731-6.
2000: Hagop M Kantarjian; Susan O'Brien; Terry L Smith; Jorge Cortes; Francis Giles; Miloslav Beran; Sherry Pierce; Yang Huh; Michael Andreeff; Charles Koller; Chul Ha; Michael J Keating; S Murphy; Emil J Freireich
Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(3):547-61.
2000: K Kaban; Andrew Lamb; Moshe Talpaz; Susan O'Brien; Jorge Cortes; Francis Giles; Sherry Pierce; Maher Albitar
Expression of thrombopoietin and its receptor (c-mpl) in chronic myelogenous leukemia: correlation with disease progression and response to therapy.
Cancer 2000;88(3):570-6.
2000: Stefan Faderl; Hagop M Kantarjian; Deborah A Thomas; Jorge Cortes; Francis Giles; Sherry Pierce; Maher Albitar; Zeev Estrov
Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia.
Leukemia & lymphoma 2000;36(3-4):263-73.
1999: S Sacchi; Hagop M Kantarjian; Susan O'Brien; Jorge Cortes; Mary Beth Rios; Francis Giles; Miloslav Beran; Charles Koller; Michael J Keating; Moshe Talpaz
Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
Cancer 1999;86(12):2632-41.
1999: Hagop M Kantarjian; Moshe Talpaz; Susan O'Brien; T Manshouri; Jorge Cortes; Francis Giles; Mary Beth Rios; C M Croce; Maher Albitar
Significance of FHIT expression in chronic myelogenous leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):4059-64.
1999: Francis Giles; Susan M O'Brien; V Santini; Varsha Gandhi; William Plunkett; John F Seymour; LE Robertson; Hagop M Kantarjian; Michael J Keating
Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: a phase II study.
Leukemia & lymphoma 1999;36(1-2):57-65.
1999: Alvaro Aguayo; Elihu Estey; Andrew Lamb; T Mansouri; Christy Gidel; Michael Keating; Francis Giles; Zeev Estrov; Bart Barlogie; Maher Albitar
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia.
Blood 1999;94(11):3717-21.
1999: S Sacchi; Hagop M Kantarjian; E J Freireich; Susan O'Brien; Jorge Cortes; Mary Beth Rios; S Kornblau; Francis Giles; Charles Koller; James L Gajewski; Moshe Talpaz
Unexpected high incidence of severe toxicities associated with alpha interferon, low-dose cytosine arabinoside and all-trans retinoic acid in patients with chronic myelogenous leukemia.
Leukemia & lymphoma 1999;35(5-6):483-9.
1999: Francis Giles; A R Keating; Razelle Kurzrock; Moshe Talpaz
A pilot study of recombinant human interleukin-4 therapy of myelofibrosis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(11):1253-5.
1999: Valeria Santini; Francis Giles
The potential of amifostine: from cytoprotectant to therapeutic agent.
Haematologica 1999;84(11):1035-42.
1999: Deborah A Thomas; Andrew Lamb; Terry L Smith; Charles Koller; Jorge Cortes; Susan O'Brien; Francis Giles; James L Gajewski; Sherry Pierce; Michael J Keating
Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy.
Cancer 1999;86(7):1216-30.
1999: Elihu H Estey; Francis Giles; Andrew Lamb; Susan O'Brien; Jorge Cortes; Emil J Freireich; Gabriel Lopez-Berestein; Michael Keating
Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia.
Blood 1999;94(7):2230-5.
1999: Miloslav Beran; Elihu Estey; Susan O'Brien; Jorge Cortes; Charles Koller; Francis Giles; Steven M Kornblau; Michael Andreeff; Norbert Vey; S R Pierce; Kimberly Hayes; G C Wong; Michael Keating; Andrew Lamb
Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2819-30.
1999: Francis Giles; Hagop M Kantarjian; Jorge Cortes; Deborah A Thomas; Moshe Talpaz; Taghi Manshouri; Maher Albitar
Multidrug resistance protein expression in chronic myeloid leukemia: associations and significance.
Cancer 1999;86(5):805-13.
1999: Farhad Ravandi-Kashani; E Estey; Jorge Cortes; L J Medeiros; Francis Giles
Granulocytic sarcoma of the pancreas: a report of two cases and literature review.
Clinical and laboratory haematology 1999;21(3):219-24.
1999: N Vey; Andrew Lamb; H Tran; Miloslav Beran; Susan O'Brien; Carol Bivins; Francis Giles; Jorge Cortes; B Cheson; Arbuck Susan; E Estey
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):577-83.
1999: Norbert Vey; Michael Keating; Francis Giles; J Cortes; Miloslav Beran; Elihu Estey
Effect of complete remission on survival in patients with acute myelogenous leukemia receiving first salvage therapy.
Blood 1999;93(9):3149-50.
1999: Jorge E Cortes; Hagop M Kantarjian; Susan O'Brien; Francis Giles; Michael J Keating; Emil J Freireich; Elihu H Estey
A pilot study of interleukin-2 for adult patients with acute myelogenous leukemia in first complete remission.
Cancer 1999;85(7):1506-13.
1999: Jorge Cortes; Susan O'Brien; Elihu Estey; Francis Giles; Michael Keating; Andrew Lamb
Phase I study of liposomal daunorubicin in patients with acute leukemia.
Investigational new drugs 1999;17(1):81-7.
1999: Hagop M Kantarjian; Susan O'Brien; Terry L Smith; Mary Beth Rios; Jorge Cortes; Miloslav Beran; Charles Koller; Francis Giles; Michael Andreeff; Steven M Kornblau; Sergio Giralt; Michael J Keating; Moshe Talpaz
Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):284-92.
1998: Miloslav Beran; Elihu Estey; Susan M O'Brien; Francis Giles; Charles Koller; Steven M Kornblau; Michael Keating; Hagop M Kantarjian
Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Leukemia & lymphoma 1998;31(5-6):521-31.
1998: Francis Giles; T J Kanemaki; R R Schreck; L Qasabian; M P Fuerst; S W Lim
Translocation (3;21;8)(q21;q22;q22) in a patient with acute myeloid leukemia. A case report and review of prognostic indicators.
Cancer genetics and cytogenetics 1998;104(1):66-9.
1998: Francis Giles
Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survival among patients with acute myeloid leukemia and stem cell transplants.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1998;26(6):1282-9.
1998: Howard Ozer; P H Wiernik; Francis Giles; C Tendler
Recombinant interferon-alpha therapy in patients with follicular lymphoma.
Cancer 1998;82(10):1821-30.
1998: Hagop M Kantarjian; Francis Giles; Susan M O'Brien; Moshe Talpaz
Clinical course and therapy of chronic myelogenous leukemia with interferon-alpha and chemotherapy.
Hematology/oncology clinics of North America 1998;12(1):31-80.
1998: Francis Giles; Susan M O'Brien; Michael J Keating
Chronic lymphocytic leukemia in (Richter's) transformation.
Seminars in oncology 1998;25(1):117-25.
1997: Francis Giles; Alan D Waxman; K N Nguyen; M P Fuerst; Donato Kusuanco; M M Franco; H Bierman; S W Lim
Comparison of Technetium-99m sestamibi and indium-111 octreotide imaging in a patient with Ewing's sarcoma before and after stem cell transplantation.
Cancer 1997;80(12 Suppl):2478-83.
1997: Alexandra M Levine; Anil Tulpule; D Tessman; L Kaplan; Francis Giles; B D Luskey; David T Scadden; Donald W Northfelt; I Silverberg; J Wernz; Byron M Espina; Daniel Von Hoff
Mitoguazone therapy in patients with refractory or relapsed AIDS-related lymphoma: results from a multicenter phase II trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(3):1094-103.
1997: A P Jewell; C P Worman; Francis Giles; Anthony H Goldstone
Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy.
Leukemia & lymphoma 1997;24(3-4):327-33.
1996: Michael W Kattan; Y Inoue; Francis Giles; Moshe Talpaz; Howard Ozer; françois guilhot; E Zuffa; S L Huber; J Robert Beck
Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
Annals of internal medicine 1996;125(7):541-8.
1996: A P Jewell; Francis Giles
Cutaneous manifestation of leishmaniasis 40 years after exposure in a patient with chronic lymphocytic leukaemia.
Leukemia & lymphoma 1996;21(3-4):347-9.
1996: R M Look; S W Lim; Alan D Waxman; P K Gupta; M M Fuerst; D A Kusuanco; G N Lawrence; Francis Giles
Technetium-99m sestamibi scanning in multiple myeloma stem cell transplantation.
Leukemia & lymphoma 1996;20(5-6):453-6.
1996: S W Lim; R E Falk; R M Look; M M Fuerst; G N Lawrence; D A Kusuanco; Francis Giles
Translocation (12;15)(p13;q13) in a patient with relapsed acute myeloid leukemia.
Cancer genetics and cytogenetics 1996;86(2):165-7.
1995: Francis Giles
Current therapy of refractory multiple myeloma.
Stem cells (Dayton, Ohio) 1995;13 Suppl 2():88-105.
1995: R M Look; S W Lim; R R Schreck; S Lee; M P Fuerst; G N Lawrence; D A Kusuanco; C E Kessler; Francis Giles
Burkitt translocation (8;22)(q24;q11) in a patient with multiple myeloma.
Cancer genetics and cytogenetics 1995;82(2):100-2.
1995: A P Jewell; Peter M Lydyard; C P Worman; Francis Giles; Anthony H Goldstone
Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without stimulating proliferation.
Leukemia & lymphoma 1995;18(1-2):159-62.
1995: Francis Giles
Refractory multiple myeloma: recent advances in therapy.
Hematologic pathology 1995;9(3-4):121-40.
1994: A P Jewell; C P Worman; Peter M Lydyard; Kwee Yong; Francis Giles; Anthony H Goldstone
Interferon-alpha up-regulates bcl-2 expression and protects B-CLL cells from apoptosis in vitro and in vivo.
British journal of haematology 1994;88(2):268-74.
1994: E N McSweeney; Francis Giles; Anthony H Goldstone
Recombinant interferon-alpha 2 antibodies in chronic lymphocytic leukemia.
Journal of interferon research 1994;14(4):191-2.
1994: Francis Giles
Multiple myeloma and other differentiated B-cell disorders.
Current opinion in hematology 1994;1(4):278-84.
1994: Francis Giles; H Phillip Koeffler
Secondary myelodysplastic syndromes and leukemias.
Current opinion in hematology 1994;1(4):256-60.
1994: A P Jewell; Kwee Yong; C P Worman; C P Tsakona; Francis Giles; Anthony H Goldstone
Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL.
British journal of haematology 1994;86(2):441-3.
1993: E N McSweeney; Francis Giles; C P Worman; A P Jewel; C P Tsakona; A V Hoffbrand; A B Mehta; Adrian C Newland; J C Cawley; D Galvani
Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia.
British journal of haematology 1993;85(1):77-83.
1992: A P Jewell; C P Worman; Francis Giles; Anthony H Goldstone; Peter M Lydyard
Resistance of chronic lymphocytic leukaemia cells to interferon-alpha generated lymphokine activated killer cells.
Leukemia & lymphoma 1992;7(5-6):473-80.
1992: Francis Giles; R Aitchison; Denise Syndercombe-Court; S Schey; Adrian C Newland
Recombinant alpha 2B interferon in combination with oral chemotherapy in late chronic phase chronic myeloid leukaemia.
Leukemia & lymphoma 1992;7(1-2):99-102.
1992: A P Jewell; Kwee Yong; C P Worman; Francis Giles; Anthony H Goldstone; Peter M Lydyard
Cytokine induction of leucocyte adhesion molecule-1 (LAM- 1) expression on chronic lymphocytic leukaemia cells.
Leukemia 1992;6(5):400-4.
1992: Francis Giles; E N McSweeney; J D Richards; J S Tobias; E J Gaminara; I R Grant; J W Kearney; Adrian C Newland; N E Parker; S Schey
Prospective randomised study of double hemi-body irradiation with and without subsequent maintenance recombinant alpha 2b interferon on survival in patients with relapsed multiple myeloma.
European journal of cancer (Oxford, England : 1990) 1992;28A(8-9):1392-5.
1991: Francis Giles; Howard Ozer
alpha-Interferon in hematological malignancies.
Current opinion in biotechnology 1991;2(6):847-50.
1991: Francis Giles
Maintenance therapy in the myeloproliferative disorders: the current options.
British journal of haematology 1991;79 Suppl 1():92-5.
1991: D McCarthy; J Clark; Francis Giles
The treatment of myelofibrosis with alfa-interferon.
British journal of haematology 1991;78(4):590-1.
1991: S H Lim; Francis Giles; M P Smith; Anthony H Goldstone
Bacterial infections in lymphoma patients treated with recombinant interleukin-2.
Acta haematologica 1991;85(3):135-8.
1991: S H Lim; C Worman; A Jewell; C Tsakona; Francis Giles; Anthony Goldstone
Lymphocyte activation and serine-esterase induction following recombinant interleukin-2 infusion for lymphomas and acute leukaemias.
Cancer immunology, immunotherapy : CII 1991;33(2):133-7.
1991: Francis Giles; C P Worman; A P Jewell; Anthony H Goldstone
Recombinant alpha-interferons, thyroid irradiation and thyroid disease.
Acta haematologica 1991;85(3):160-3.
1990: W C de Mel; A Victor Hoffbrand; Francis Giles; A H Goldstone; Atul B Mehta; Kanagasabai Ganeshaguru
Alpha interferon therapy for haematological malignancies: correlation between in vivo induction of the 2',5'oligoadenylate system and clinical response.
British journal of haematology 1990;74(4):452-6.
1990: Francis Giles; M P Smith; Anthony H Goldstone
Chlorambucil lung toxicity.
Acta haematologica 1990;83(3):156-8.
1989: S E Kinsey; Francis Giles; john holton
Cusum plotting of temperature charts for assessing antimicrobial treatment in neutropenic patients.
BMJ (Clinical research ed.) 1989;299(6702):775-6.
1989: P Martiat; N Ifrah; Feyruz V Rassool; G Morgan; Francis Giles; J Gow; John M Goldman
Molecular analysis of Philadelphia positive essential thrombocythemia.
Leukemia 1989;3(8):563-5.
1989: C R Singer; J S Tobias; Francis Giles; G N Rudd; G M Blackman; J D Richards
Hemibody irradiation. An effective second-line therapy in drug-resistance multiple myeloma.
Cancer 1989;63(12):2446-51.
1988: S J Russell; Francis Giles; D S Thompson; D J Scanlon; H Walker; J D Richards
Granulocytic sarcoma of the small intestine preceding acute myelomonocytic leukemia with abnormal eosinophils and inv(16).
Cancer genetics and cytogenetics 1988;35(2):231-5.
1988: P D Maurice; C Bunker; Francis Giles; A Goldstone; J Holton
Mycobacterium avium-intracellulare infection associated with hairy-cell leukemia.
Archives of dermatology 1988;124(10):1545-9.
1988: S J Russell; H Walker; Francis Giles; A H Goldstone
Ring chromosome 6 and i(17q-) in a patient with acute promyelocytic leukemia. Absence of translocation t(15;17).
Cancer genetics and cytogenetics 1988;34(2):273-6.
1988: Francis Giles; C R Singer; A G Gray; Kwee Yong; M Brozovic; Sally C Davies; I R Grant; A V Hoffbrand; S J Machin; A B Mehta
Alpha-interferon therapy for essential thrombocythaemia.
Lancet 1988;2(8602):70-2.
1988: Francis Giles; S J Russell; C P Worman; Anthony H Goldstone; J D Richards; john holton
Atypical mycobacterial infection in alpha interferon-treated hairy cell leukaemia.
Acta haematologica 1988;80(3):159-61.
1987: S J Russell; Francis Giles; D Edwards; J Porter; S Hardmann; R Harrison
Perforation of superior vena cava by indwelling central venous catheters.
Lancet 1987;1(8532):568-9.